Ernst RobertLengyel0m5sBaYMHOD5hHlsaUXv9Gq0+s+oErnst Robert Lengyel41.78927490000000-87.601250000000001942Lengyel, Ernst RobertI trained both as a scientist and as a physician and, throughout my career, I have focused on the treatment and biology of ovarian cancer (OvCa). My Ph.D. thesis was on the role of proteases in ovarian cancer and my clinical fellowship involved a special emphasis on the treatment of patients with this disease. As a surgeon and clinician, I am familiar with the presentation of ovarian cancer in patients, and experience the incredible obstacles we face in its treatment. In the laboratory, I have built the research infrastructure necessary for effective ovarian cancer research.
The Lengyel lab has elucidated, at least in part, the first critical steps of ovarian cancer metastasis by paying close attention to the host microenvironment. We have collected the 25 most commonly used ovarian cancer cell lines from all over the world, including those which are chemotherapy resistant. We have established several mouse models for OvCa, and using a genetic mouse model (K-rasG12D/+/Pten-/- -- established by Dr. Tyler Jacks), a syngeneic orthotopic mouse model using mouse OvCa cells (ID8 -- established by K. Roby), and several xenograft ip models using primary and cultured human OvCa cells. I have also established a prospective OvCa tissue bank and, together with 2 gynecologic pathologists, we have assembled 13 tissue arrays including normal tissue, borderline tumor and primary tumor, & corresponding metastasis. As a surgeon, the main focus of my practice is patients with OvCa; therefore, I will be able to enroll a substantial number of patients on the proposed clinical trial and have the infrastructure in place to collect the tissue required for the translational studies.
My clinical experience treating ovarian cancer, together with my laboratory, which focuses on OvCa biology, gives me a unique opportunity and obligation to find new treatments that can benefit patients with ovarian cancer.Professorplugins:TwitterTwitterprns:coAuthorOfcoauthor ofprns:emailEncryptedemail addressprns:endDateend dateFaculty Rankprns:fullNamefull nameprns:hasAuthorListauthor listprns:hasFacultyRankhas faculty rankprns:hasNetworkhas networkprns:hasPublicationVenuepublished inprns:informationResourceReferenceinformation resource referenceprns:isPrimaryPositionis primary positionprns:latitudelatitudeprns:longitudelongitudeprns:mainImagephotoprns:maxWeightmaximum weightprns:medlineTAjournal title abbreviationprns:meshDescriptorUIMeSH DescriptorUIprns:meshSemanticGroupNameMeSH semantic group nameprns:minWeightminimum weightprns:numberOfAuthorsnumber of authorsprns:numberOfConnectionsnumber of connectionsprns:numberOfPublicationsnumber of publicationsprns:personIdPerson IDprns:personInPrimaryPositionperson in primary positionprns:physicalNeighborOfphysical neighborprns:pluginSearchableDataProfilesRNS Plugin Searchable Dataprns:positionInDepartmentposition in departmentprns:predicateNodepredicate nodeprns:publicationDatepublication dateprns:similarTosimilar toprns:sortOrdersort orderprns:trainingAtOrganizationeducational organizationprns:trainingLocationtraining locationprns:uniquenessWeightuniqueness weightprns:yearyearAcademic ArticleArticleDocumentbibo:pmidPubMed IdentifierAddressvivo:addressCitycityvivo:addressPostalCodepostal codevivo:addressStatestate or provincevivo:authorInAuthorshipselected publicationsvivo:authorRankauthor rank in publicationAuthorshipvivo:degreeEarneddegree earnedDepartmentvivo:educationalTrainingeducation and trainingEducational Trainingvivo:hasResearchArearesearch areasvivo:hrJobTitleHR job titleInformation Resourcevivo:linkAnchorTextlink anchor textvivo:linkedAuthorlinked authorvivo:linkedInformationResourcelinked information resourcevivo:mailingAddressmailing addressvivo:majorFieldmajor field of degreevivo:overviewoverviewvivo:personInPositionpositionsPositionvivo:positionInOrganizationposition in organizationvivo:preferredTitlepreferred titleURLLinkvivo:webpagewebpagerdf:predicatepredicaterdf:typetyperdfs:labellabelConceptAgentfoaf:firstNamefirst namefoaf:lastNamelast nameOrganizationPersonAuthorship 1000912Authorship 10066410Authorship 1002113Authorship 1009668Authorship 99901527948864Temkin SM, Lengyel E, Tergas A, Terplan MJournal of clinical oncology : official journal of the American Society of Clinical OncologyOvarian cancer treatment in black and white women: A comparison of clinico-pathologic factors and outcome. J Clin Oncol. 2008 May 20; 26(15_suppl):16531.J Clin Oncol2008-05-20T00:00:002008Ovarian cancer treatment in black and white women: A comparison of clinico-pathologic factors and outcome.28201526Gerhard M, Neumayer N, Presecan-Siedel E, Zanner R, Lengyel E, Cramer T, Ho Cker M, Prinz CEndocrinologyGastrin Induces Expression and Promoter Activity of the Vesicular Monoamine Transporter Subtype 2. Endocrinology. 2001 Aug 01; 142(8):3663-3672.Endocrinology2001-08-01T00:00:002001Gastrin Induces Expression and Promoter Activity of the Vesicular Monoamine Transporter Subtype 2.28202518Sundaram KM, Zhang Y, Mitra AK, Kouadio JK, Gwin K, Kossiakoff AA, Roman BB, Lengyel E, Piccirilli JACancer researchProlactin Receptor-Mediated Internalization of Imaging Agents Detects Epithelial Ovarian Cancer with Enhanced Sensitivity and Specificity. Cancer Res. 2017 04 01; 77(7):1684-1696.Cancer Res2017-02-15T00:00:002017Prolactin Receptor-Mediated Internalization of Imaging Agents Detects Epithelial Ovarian Cancer with Enhanced Sensitivity and Specificity.28257705Mukherjee A, Kenny HA, Lengyel ECell stem cellUnsaturated Fatty Acids Maintain Cancer Cell Stemness. Cell Stem Cell. 2017 03 02; 20(3):291-292.Cell Stem Cell2017-03-02T00:00:002017Unsaturated Fatty Acids Maintain Cancer Cell Stemness.28264838Chiyoda T, Hart PC, Eckert MA, McGregor SM, Lastra RR, Hamamoto R, Nakamura Y, Yamada SD, Olopade OI, Lengyel E, Romero ILCancer prevention research (Philadelphia, Pa.)Loss of BRCA1 in the Cells of Origin of Ovarian Cancer Induces Glycolysis: A Window of Opportunity for Ovarian Cancer Chemoprevention. Cancer Prev Res (Phila). 2017 Apr; 10(4):255-266.Cancer Prev Res (Phila)2017-03-06T00:00:002017Loss of BRCA1 in the Cells of Origin of Ovarian Cancer Induces Glycolysis: A Window of Opportunity for Ovarian Cancer Chemoprevention.Authorship 102189428346091Lal-Nag M, McGee L, Guha R, Lengyel E, Kenny HA, Ferrer MSLAS discovery : advancing life sciences R & DA High-Throughput Screening Model of the Tumor Microenvironment for Ovarian Cancer Cell Growth. SLAS Discov. 2017 06; 22(5):494-506.SLAS Discov2017-01-31T00:00:002017A High-Throughput Screening Model of the Tumor Microenvironment for Ovarian Cancer Cell Growth.Authorship 105754528456378Veneris JT, Darcy KM, Mhawech-Fauceglia P, Tian C, Lengyel E, Lastra RR, Pejovic T, Conzen SD, Fleming GFGynecologic oncologyHigh glucocorticoid receptor expression predicts short progression-free survival in ovarian cancer. Gynecol Oncol. 2017 07; 146(1):153-160.Gynecol Oncol2017-04-26T00:00:002017High glucocorticoid receptor expression predicts short progression-free survival in ovarian cancer.Obstetrics and GynecologyRadiation and Cellular OncologyAuthorship 1129146Authorship 1145081Authorship 11255218Authorship 11676619Authorship 12058313Authorship 1223744Authorship 1235159Authorship 1244683Authorship 1187523Authorship 1240155Authorship 1231832Authorship 124612830241606Coscia F, Lengyel E, Duraiswamy J, Ashcroft B, Bassani-Sternberg M, Wierer M, Johnson A, Wroblewski K, Montag A, Yamada SD, López-Méndez B, Nilsson J, Mund A, Mann M, Curtis MCellMulti-level Proteomics Identifies CT45 as a Chemosensitivity Mediator and Immunotherapy Target in Ovarian Cancer. Cell. 2018 09 20; 175(1):159-170.e16.Cell2018-09-20T00:00:002018Multi-level Proteomics Identifies CT45 as a Chemosensitivity Mediator and Immunotherapy Target in Ovarian Cancer.29720506Matsuda T, Leisegang M, Park JH, Ren L, Kato T, Ikeda Y, Harada M, Kiyotani K, Lengyel E, Fleming GF, Nakamura YClinical cancer research : an official journal of the American Association for Cancer ResearchInduction of Neoantigen-Specific Cytotoxic T Cells and Construction of T-cell Receptor-Engineered T Cells for Ovarian Cancer. Clin Cancer Res. 2018 11 01; 24(21):5357-5367.Clin Cancer Res2018-05-02T00:00:002018Induction of Neoantigen-Specific Cytotoxic T Cells and Construction of T-cell Receptor-Engineered T Cells for Ovarian Cancer.30396040Loessner D, Rockstroh A, Shokoohmand A, Holzapfel BM, Wagner F, Baldwin J, Boxberg M, Schmalfeldt B, Lengyel E, Clements JA, Hutmacher DWBiomaterialsA 3D tumor microenvironment regulates cell proliferation, peritoneal growth and expression patterns. Biomaterials. 2019 01; 190-191:63-75.Biomaterials2018-10-16T00:00:002018A 3D tumor microenvironment regulates cell proliferation, peritoneal growth and expression patterns.29176560Li G, Montgomery JE, Eckert MA, Chang JW, Tienda SM, Lengyel E, Moellering RENature communicationsAn activity-dependent proximity ligation platform for spatially resolved quantification of active enzymes in single cells. Nat Commun. 2017 11 24; 8(1):1775.Nat Commun2017-11-24T00:00:002017An activity-dependent proximity ligation platform for spatially resolved quantification of active enzymes in single cells.29128106Hoppenot C, Eckert MA, Tienda SM, Lengyel EGynecologic oncologyWho are the long-term survivors of high grade serous ovarian cancer? Gynecol Oncol. 2018 01; 148(1):204-212.Gynecol Oncol2017-11-08T00:00:002017Who are the long-term survivors of high grade serous ovarian cancer?29398710Ladanyi A, Mukherjee A, Kenny HA, Johnson A, Mitra AK, Sundaresan S, Nieman KM, Pascual G, Benitah SA, Montag A, Yamada SD, Abumrad NA, Lengyel EOncogeneAdipocyte-induced CD36 expression drives ovarian cancer progression and metastasis. Oncogene. 2018 04; 37(17):2285-2301.Oncogene2018-02-05T00:00:002018Adipocyte-induced CD36 expression drives ovarian cancer progression and metastasis.30154548Liu J, Eckert MA, Harada BT, Liu SM, Lu Z, Yu K, Tienda SM, Chryplewicz A, Zhu AC, Yang Y, Huang JT, Chen SM, Xu ZG, Leng XH, Yu XC, Cao J, Zhang Z, Liu J, Lengyel E, He CNature cell biologym6A mRNA methylation regulates AKT activity to promote the proliferation and tumorigenicity of endometrial cancer. Nat Cell Biol. 2018 09; 20(9):1074-1083.Nat Cell Biol2018-08-27T00:00:002018m6A mRNA methylation regulates AKT activity to promote the proliferation and tumorigenicity of endometrial cancer.30471899Javellana M, Hoppenot C, Lengyel EGynecologic oncologyThe road to long-term survival: Surgical approach and longitudinal treatments of long-term survivors of advanced-stage serous ovarian cancer. Gynecol Oncol. 2019 02; 152(2):228-234.Gynecol Oncol2018-11-22T00:00:002018The road to long-term survival: Surgical approach and longitudinal treatments of long-term survivors of advanced-stage serous ovarian cancer.30174305Curtis M, Kenny HA, Ashcroft B, Mukherjee A, Johnson A, Zhang Y, Helou Y, Batlle R, Liu X, Gutierrez N, Gao X, Yamada SD, Lastra R, Montag A, Ahsan N, Locasale JW, Salomon AR, Nebreda AR, Lengyel ECell metabolismFibroblasts Mobilize Tumor Cell Glycogen to Promote Proliferation and Metastasis. Cell Metab. 2019 01 08; 29(1):141-155.e9.Cell Metab2018-08-30T00:00:002018Fibroblasts Mobilize Tumor Cell Glycogen to Promote Proliferation and Metastasis.21867090Lengyel E, Nicklas M, Jeevan HS, Geibel C, Steglich FPhysical review lettersPressure tuning of the interplay of magnetism and superconductivity in CeCu2Si2. Phys Rev Lett. 2011 Jul 29; 107(5):057001.Phys Rev Lett2011-07-28T00:00:002011Pressure tuning of the interplay of magnetism and superconductivity in CeCu2Si2.29709261Lengyel E, Makowski L, DiGiovanni J, Kolonin MGTrends in cancerCancer as a Matter of Fat: The Crosstalk between Adipose Tissue and Tumors. Trends Cancer. 2018 05; 4(5):374-384.Trends Cancer2018-04-05T00:00:002018Cancer as a Matter of Fat: The Crosstalk between Adipose Tissue and Tumors.30064659Curtis M, Mukherjee A, Lengyel ETrends in cancerThe Tumor Microenvironment Takes Center Stage in Ovarian Cancer Metastasis. Trends Cancer. 2018 08; 4(8):517-519.Trends Cancer2018-06-22T00:00:002018The Tumor Microenvironment Takes Center Stage in Ovarian Cancer Metastasis.06/1992University of MunichMunichUniversity of Munich, M.D.M.D.M.D.Authorship 125790530567719Lee W, Ko SY, Mohamed MS, Kenny HA, Lengyel E, Naora HThe Journal of experimental medicineNeutrophils facilitate ovarian cancer premetastatic niche formation in the omentum. J Exp Med. 2019 01 07; 216(1):176-194.J Exp Med2018-12-19T00:00:002018Neutrophils facilitate ovarian cancer premetastatic niche formation in the omentum.Authorship 1266471130655321Hart PC, Chiyoda T, Liu X, Weigert M, Curtis M, Chiang CY, Loth R, Lastra R, McGregor SM, Locasale JW, Lengyel E, Romero ILMolecular cancer research : MCRSPHK1 Is a Novel Target of Metformin in Ovarian Cancer. Mol Cancer Res. 2019 04; 17(4):870-881.Mol Cancer Res2019-01-17T00:00:002019SPHK1 Is a Novel Target of Metformin in Ovarian Cancer.Authorship 123671Authorship 119942Authorship 1279768Authorship 1279822Authorship 1283192630807370Chapel DB, Lengyel E, Ritterhouse LL, Lastra RRInternational journal of gynecological pathology : official journal of the International Society of Gynecological PathologistsInterpretation of Mismatch Repair Protein Immunohistochemistry in Endometrial Carcinoma Should Consider Both Lynch Syndrome Screening and Immunotherapy Susceptibility: An Illustrative Case Report. Int J Gynecol Pathol. 2020 May; 39(3):233-237.Int J Gynecol Pathol2020-05-01T00:00:002020Interpretation of Mismatch Repair Protein Immunohistochemistry in Endometrial Carcinoma Should Consider Both Lynch Syndrome Screening and Immunotherapy Susceptibility: An Illustrative Case Report.30835824Bast RC, Matulonis UA, Sood AK, Ahmed AA, Amobi AE, Balkwill FR, Wielgos-Bonvallet M, Bowtell DDL, Brenton JD, Brugge JS, Coleman RL, Draetta GF, Doberstein K, Drapkin RI, Eckert MA, Edwards RP, Elias KM, Ennis D, Futreal A, Gershenson DM, Greenberg RA, Huntsman DG, Ji JXY, Kohn EC, Iavarone C, Lengyel ER, Levine DA, Lord CJ, Lu Z, Mills GB, Modugno F, Nelson BH, Odunsi K, Pilsworth JA, Rottapel RK, Powell DJ, Shen L, Shih IM, Spriggs DR, Walton J, Zhang K, Zhang R, Zou LCancerCritical questions in ovarian cancer research and treatment: Report of an American Association for Cancer Research Special Conference. Cancer. 2019 06 15; 125(12):1963-1972.Cancer2019-03-05T00:00:002019Critical questions in ovarian cancer research and treatment: Report of an American Association for Cancer Research Special Conference.30797592McGuire S, Kara B, Hart PC, Montag A, Wroblewski K, Fazal S, Huang XY, Lengyel E, Kenny HAGynecologic oncologyInhibition of fascin in cancer and stromal cells blocks ovarian cancer metastasis. Gynecol Oncol. 2019 05; 153(2):405-415.Gynecol Oncol2019-02-20T00:00:002019Inhibition of fascin in cancer and stromal cells blocks ovarian cancer metastasis.Authorship 128426530914657Chryplewicz A, Tienda SM, Nahotko DA, Peters PN, Lengyel E, Eckert MAScientific reportsMutant p53 regulates LPA signaling through lysophosphatidic acid phosphatase type 6. Sci Rep. 2019 03 26; 9(1):5195.Sci Rep2019-03-26T00:00:002019Mutant p53 regulates LPA signaling through lysophosphatidic acid phosphatase type 6.Authorship 124801Authorship 162431Authorship 134283Authorship 135831Authorship 159215Authorship 153788Authorship 1292701931043742Eckert MA, Coscia F, Chryplewicz A, Chang JW, Hernandez KM, Pan S, Tienda SM, Nahotko DA, Li G, Blaženovic I, Lastra RR, Curtis M, Yamada SD, Perets R, McGregor SM, Andrade J, Fiehn O, Moellering RE, Mann M, Lengyel ENatureProteomics reveals NNMT as a master metabolic regulator of cancer-associated fibroblasts. Nature. 2019 05; 569(7758):723-728.Nature2019-05-01T00:00:002019Proteomics reveals NNMT as a master metabolic regulator of cancer-associated fibroblasts.Authorship 183072Authorship 160425Authorship 149005Authorship 189105Authorship 227374Authorship 179466Authorship 187293Authorship 186347Authorship 190731Authorship 1931118Authorship 194011Authorship 212798Authorship 257477Authorship 130866231311654Dauer P, Lengyel ETrends in cancerNew Roles for Glycogen in Tumor Progression. Trends Cancer. 2019 07; 5(7):396-399.Trends Cancer2019-05-31T00:00:002019New Roles for Glycogen in Tumor Progression.Authorship 252442Authorship 256811Authorship 285696D010051Disorders1667380.613542Ovarian NeoplasmsAuthorship 297799Authorship 322584Authorship 1330791431562255Kenny HA, Lal-Nag M, Shen M, Kara B, Nahotko DA, Wroblewski K, Fazal S, Chen S, Chiang CY, Chen YJ, Brimacombe KR, Marugan J, Ferrer M, Lengyel EMolecular cancer therapeuticsQuantitative High-Throughput Screening Using an Organotypic Model Identifies Compounds that Inhibit Ovarian Cancer Metastasis. Mol Cancer Ther. 2020 01; 19(1):52-62.Mol Cancer Ther2019-09-27T00:00:002019Quantitative High-Throughput Screening Using an Organotypic Model Identifies Compounds that Inhibit Ovarian Cancer Metastasis.Authorship 333448Authorship 324338Authorship 133477631591248Li G, Eckert MA, Chang JW, Montgomery JE, Chryplewicz A, Lengyel E, Moellering REProceedings of the National Academy of Sciences of the United States of AmericaUltrasensitive, multiplexed chemoproteomic profiling with soluble activity-dependent proximity ligation. Proc Natl Acad Sci U S A. 2019 10 22; 116(43):21493-21500.Proc Natl Acad Sci U S A2019-10-07T00:00:002019Ultrasensitive, multiplexed chemoproteomic profiling with soluble activity-dependent proximity ligation.Authorship 373632Authorship 3152012Authorship 133730731646189Ko SY, Lee W, Kenny HA, Dang LH, Ellis LM, Jonasch E, Lengyel E, Naora HCommunications biologyCancer-derived small extracellular vesicles promote angiogenesis by heparin-bound, bevacizumab-insensitive VEGF, independent of vesicle uptake. Commun Biol. 2019; 2:386.Commun Biol2019-10-18T00:00:002019Cancer-derived small extracellular vesicles promote angiogenesis by heparin-bound, bevacizumab-insensitive VEGF, independent of vesicle uptake.Authorship 3914610Authorship 306975Authorship 324148Authorship 432406Authorship 392437Authorship 321453Authorship 3614616Authorship 1348911031851935Hart PC, Kenny HA, Grassl N, Watters KM, Litchfield LM, Coscia F, Blaženovic I, Ploetzky L, Fiehn O, Mann M, Lengyel E, Romero ILCell reportsMesothelial Cell HIF1a Expression Is Metabolically Downregulated by Metformin to Prevent Oncogenic Tumor-Stromal Crosstalk. Cell Rep. 2019 12 17; 29(12):4086-4098.e6.Cell Rep2019-12-17T00:00:002019Mesothelial Cell HIF1a Expression Is Metabolically Downregulated by Metformin to Prevent Oncogenic Tumor-Stromal Crosstalk.Authorship 134974931870409Zhang Z, Zhan Q, Eckert M, Zhu A, Chryplewicz A, De Jesus DF, Ren D, Kulkarni RN, Lengyel E, He C, Chen MGenome biologyRADAR: differential analysis of MeRIP-seq data with a random effect model. Genome Biol. 2019 12 23; 20(1):294.Genome Biol2019-12-23T00:00:002019RADAR: differential analysis of MeRIP-seq data with a random effect model.Authorship 336168Authorship 135180731925178Ko SY, Lee W, Kenny HA, Dang LH, Ellis LM, Jonasch E, Lengyel E, Naora HCommunications biologyCancer-derived small extracellular vesicles promote angiogenesis by heparin-bound, bevacizumab-insensitive VEGF, independent of vesicle uptake. Commun Biol. 2019 Oct 18; 2(1):386.Commun Biol2019-10-18T00:00:002019Cancer-derived small extracellular vesicles promote angiogenesis by heparin-bound, bevacizumab-insensitive VEGF, independent of vesicle uptake.Authorship 3469214Authorship 434342Authorship 437527Authorship 471108Authorship 346983Authorship 345074Authorship 491027Authorship 135790932054768Mukherjee A, Chiang CY, Daifotis HA, Nieman KM, Fahrmann JF, Lastra RR, Romero IL, Fiehn O, Lengyel ECancer researchAdipocyte-Induced FABP4 Expression in Ovarian Cancer Cells Promotes Metastasis and Mediates Carboplatin Resistance. Cancer Res. 2020 04 15; 80(8):1748-1761.Cancer Res2020-02-13T00:00:002020Adipocyte-Induced FABP4 Expression in Ovarian Cancer Cells Promotes Metastasis and Mediates Carboplatin Resistance.Authorship 4621915Authorship 465194Authorship 353132Authorship 362323Authorship 136382632154592Coscia F, Doll S, Bech JM, Schweizer L, Mund A, Lengyel E, Lindebjerg J, Madsen GI, Moreira JM, Mann MThe Journal of pathologyA streamlined mass spectrometry-based proteomics workflow for large-scale FFPE tissue analysis. J Pathol. 2020 05; 251(1):100-112.J Pathol2020-05-01T00:00:002020A streamlined mass spectrometry-based proteomics workflow for large-scale FFPE tissue analysis.Authorship 419801Authorship 387713Authorship 4146210Authorship 136698232268038Adeleye A, Lengyel EThe New England journal of medicineCare of Transgender Persons. N Engl J Med. 2020 04 09; 382(15):1481-1482.N Engl J Med2020-04-09T00:00:002020Care of Transgender Persons.Authorship 393799Authorship 97171Authorship 91401Authorship 91993Authorship 450738Authorship 89251Authorship 4335110Authorship 441983Authorship 452934Authorship 4665413Authorship 448619Authorship 493946Authorship 4646211Authorship 87312Authorship 175528Authorship 192315Authorship 140192232820089Sackeim MG, Lengyel EPostgraduate medical journalHealthy food for trainees: a call to action. Postgrad Med J. 2021 Nov; 97(1153):740-741.Postgrad Med J2020-08-20T00:00:002020Healthy food for trainees: a call to action.Authorship 259064Authorship 140282332840618Alter R, Turaga K, Lengyel EJAMA network openAre We Ready for Hyperthermic Intraperitoneal Chemotherapy in the Upfront Treatment of Ovarian Cancer? JAMA Netw Open. 2020 08 03; 3(8):e2014184.JAMA Netw Open2020-08-03T00:00:002020Are We Ready for Hyperthermic Intraperitoneal Chemotherapy in the Upfront Treatment of Ovarian Cancer?Authorship 315371Authorship 361734Authorship 3830611Authorship 385784Authorship 401262Authorship 402283Authorship 4410628761947Lengyel E, Gum R, Stepp E, Juarez J, Wang H, Boyd DJournal of cellular biochemistryRegulation of urokinase-type plasminogen activator expression by an ERK1-dependent signaling pathway in a squamous cell carcinoma cell line. J Cell Biochem. 1996 Jun 01; 61(3):430-43.J Cell Biochem1996-06-01T00:00:001996Regulation of urokinase-type plasminogen activator expression by an ERK1-dependent signaling pathway in a squamous cell carcinoma cell line.8798512Lengyel E, Wang H, Stepp E, Juarez J, Wang Y, Doe W, Pfarr CM, Boyd DThe Journal of biological chemistryRequirement of an upstream AP-1 motif for the constitutive and phorbol ester-inducible expression of the urokinase-type plasminogen activator receptor gene. J Biol Chem. 1996 Sep 20; 271(38):23176-84.J Biol Chem1996-09-20T00:00:001996Requirement of an upstream AP-1 motif for the constitutive and phorbol ester-inducible expression of the urokinase-type plasminogen activator receptor gene.9664142Jacob K, Wach F, Holzapfel U, Hein R, Lengyel E, Buettner R, Bosserhoff AKMelanoma researchIn vitro modulation of human melanoma cell invasion and proliferation by all-trans-retinoic acid. Melanoma Res. 1998 Jun; 8(3):211-9.Melanoma Res1998-06-01T00:00:001998In vitro modulation of human melanoma cell invasion and proliferation by all-trans-retinoic acid.9816144Schaller G, Fuchs I, Pritze W, Ebert A, Herbst H, Pantel K, Weitzel H, Lengyel EClinical cancer research : an official journal of the American Association for Cancer ResearchElevated keratin 18 protein expression indicates a favorable prognosis in patients with breast cancer. Clin Cancer Res. 1996 Nov; 2(11):1879-85.Clin Cancer Res1996-11-01T00:00:001996Elevated keratin 18 protein expression indicates a favorable prognosis in patients with breast cancer.10347197Ried S, Jäger C, Jeffers M, Vande Woude GF, Graeff H, Schmitt M, Lengyel EThe Journal of biological chemistryActivation mechanisms of the urokinase-type plasminogen activator promoter by hepatocyte growth factor/scatter factor. J Biol Chem. 1999 Jun 04; 274(23):16377-86.J Biol Chem1999-06-04T00:00:001999Activation mechanisms of the urokinase-type plasminogen activator promoter by hepatocyte growth factor/scatter factor.9191056Lengyel E, Wang H, Gum R, Simon C, Wang Y, Boyd DOncogeneElevated urokinase-type plasminogen activator receptor expression in a colon cancer cell line is due to a constitutively activated extracellular signal-regulated kinase-1-dependent signaling cascade. Oncogene. 1997 May 29; 14(21):2563-73.Oncogene1997-05-29T00:00:001997Elevated urokinase-type plasminogen activator receptor expression in a colon cancer cell line is due to a constitutively activated extracellular signal-regulated kinase-1-dependent signaling cascade.Authorship 1416141233088423Vickman RE, Faget DV, Beachy P, Beebe D, Bhowmick NA, Cukierman E, Deng WM, Granneman JG, Hildesheim J, Kalluri R, Lau KS, Lengyel E, Lundeberg J, Moscat J, Nelson PS, Pietras K, Politi K, Puré E, Scherz-Shouval R, Sherman MH, Tuveson D, Weeraratna AT, White RM, Wong MH, Woodhouse EC, Zheng Y, Hayward SW, Stewart SAOncotargetDeconstructing tumor heterogeneity: the stromal perspective. Oncotarget. 2020 Oct 06; 11(40):3621-3632.Oncotarget2020-10-06T00:00:002020Deconstructing tumor heterogeneity: the stromal perspective.9136992Gum R, Wang H, Lengyel E, Juarez J, Boyd DOncogeneRegulation of 92 kDa type IV collagenase expression by the jun aminoterminal kinase- and the extracellular signal-regulated kinase-dependent signaling cascades. Oncogene. 1997 Mar 27; 14(12):1481-93.Oncogene1997-03-27T00:00:001997Regulation of 92 kDa type IV collagenase expression by the jun aminoterminal kinase- and the extracellular signal-regulated kinase-dependent signaling cascades.10209854Schaller G, Fuchs I, Ebert A, Gstettenbauer M, Herbst H, Lengyel EZentralblatt fur Gynakologie[The clinical importance of keratin 18 in breast cancer]. Zentralbl Gynakol. 1999; 121(3):126-30.Zentralbl Gynakol1999-01-01T00:00:001999[The clinical importance of keratin 18 in breast cancer].11238946Hapke S, Gawaz M, Dehne K, Köhler J, Marshall JF, Graeff H, Schmitt M, Reuning U, Lengyel EMolecular and cellular biologybeta(3)A-integrin downregulates the urokinase-type plasminogen activator receptor (u-PAR) through a PEA3/ets transcriptional silencing element in the u-PAR promoter. Mol Cell Biol. 2001 Mar; 21(6):2118-32.Mol Cell Biol2001-03-01T00:00:002001beta(3)A-integrin downregulates the urokinase-type plasminogen activator receptor (u-PAR) through a PEA3/ets transcriptional silencing element in the u-PAR promoter.11331280Hapke S, Kessler H, Arroyo de Prada N, Benge A, Schmitt M, Lengyel E, Reuning UThe Journal of biological chemistryIntegrin alpha(v)beta(3)/vitronectin interaction affects expression of the urokinase system in human ovarian cancer cells. J Biol Chem. 2001 Jul 13; 276(28):26340-8.J Biol Chem2001-04-30T00:00:002001Integrin alpha(v)beta(3)/vitronectin interaction affects expression of the urokinase system in human ovarian cancer cells.11459816Gerhard M, Neumayer N, Presecan-Siedel E, Zanner R, Lengyel E, Cramer T, Höcker M, Prinz CEndocrinologyGastrin induces expression and promoter activity of the vesicular monoamine transporter subtype 2. Endocrinology. 2001 Aug; 142(8):3663-72.Endocrinology2001-08-01T00:00:002001Gastrin induces expression and promoter activity of the vesicular monoamine transporter subtype 2.10417621Marschall C, Lengyel E, Nobutoh T, Braungart E, Douwes K, Simon A, Magdolen V, Reuning U, Degitz KThe Journal of investigative dermatologyUVB increases urokinase-type plasminogen activator receptor (uPAR) expression. J Invest Dermatol. 1999 Jul; 113(1):69-76.J Invest Dermatol1999-07-01T00:00:001999UVB increases urokinase-type plasminogen activator receptor (uPAR) expression.11267133Iesalnieks I, Rentsch M, Lengyel E, Mirwald T, Jauch K, Beham ATransplantation proceedingsJNK and p38MAPK are activated during graft reperfusion and not during cold storage in rat liver transplantation. Transplant Proc. 2001 Feb-Mar; 33(1-2):931-2.Transplant Proc2001-02-01T00:00:002001JNK and p38MAPK are activated during graft reperfusion and not during cold storage in rat liver transplantation.33215053Reizine N, Peterson B, Moya S, Wang Y, Tan YCYH, Eng OS, Bilimoria M, Lengyel E, Turaga K, Catenacci DVTJCO precision oncologyComplete Response in a Patient With Chemorefractory EGFR-Amplified, PD-L1-Positive Metastatic Gastric Cancer Treated By Dual Anti-EGFR and Anti-PD-1 Monoclonal Antibody Therapy. JCO Precis Oncol. 2020; 4.JCO Precis Oncol2020-10-02T00:00:002020Complete Response in a Patient With Chemorefractory EGFR-Amplified, PD-L1-Positive Metastatic Gastric Cancer Treated By Dual Anti-EGFR and Anti-PD-1 Monoclonal Antibody Therapy.Authorship 142313810871853Schnelzer A, Prechtel D, Knaus U, Dehne K, Gerhard M, Graeff H, Harbeck N, Schmitt M, Lengyel EOncogeneRac1 in human breast cancer: overexpression, mutation analysis, and characterization of a new isoform, Rac1b. Oncogene. 2000 Jun 15; 19(26):3013-20.Oncogene2000-06-15T00:00:002000Rac1 in human breast cancer: overexpression, mutation analysis, and characterization of a new isoform, Rac1b.11004363Hannke-Lohmann A, Pildner von Steinburg S, Dehne K, Benard V, Kolben M, Schmitt M, Lengyel EObstetrics and gynecologyDownregulation of a mitogen-activated protein kinase signaling pathway in the placentas of women with preeclampsia. Obstet Gynecol. 2000 Oct; 96(4):582-7.Obstet Gynecol2000-10-01T00:00:002000Downregulation of a mitogen-activated protein kinase signaling pathway in the placentas of women with preeclampsia.11489818Schmalfeldt B, Prechtel D, H?rting K, Sp?the K, Rutke S, Konik E, Fridman R, Berger U, Schmitt M, Kuhn W, Lengyel EClinical cancer research : an official journal of the American Association for Cancer ResearchIncreased expression of matrix metalloproteinases (MMP)-2, MMP-9, and the urokinase-type plasminogen activator is associated with progression from benign to advanced ovarian cancer. Clin Cancer Res. 2001 Aug; 7(8):2396-404.Clin Cancer Res2001-08-01T00:00:002001Increased expression of matrix metalloproteinases (MMP)-2, MMP-9, and the urokinase-type plasminogen activator is associated with progression from benign to advanced ovarian cancer.Authorship 142596333278287Kurnit KC, Fleming GF, Lengyel EObstetrics and gynecologyUpdates and New Options in Advanced Epithelial Ovarian Cancer Treatment. Obstet Gynecol. 2021 01 01; 137(1):108-121.Obstet Gynecol2021-01-01T00:00:002021Updates and New Options in Advanced Epithelial Ovarian Cancer Treatment.12796395Schewe DM, Leupold JH, Boyd DD, Lengyel ER, Wang H, Gruetzner KU, Schildberg FW, Jauch KW, Allgayer HClinical cancer research : an official journal of the American Association for Cancer ResearchTumor-specific transcription factor binding to an activator protein-2/Sp1 element of the urokinase-type plasminogen activator receptor promoter in a first large series of resected gastrointestinal cancers. Clin Cancer Res. 2003 Jun; 9(6):2267-76.Clin Cancer Res2003-06-01T00:00:002003Tumor-specific transcription factor binding to an activator protein-2/Sp1 element of the urokinase-type plasminogen activator receptor promoter in a first large series of resected gastrointestinal cancers.12244126Besta F, Massberg S, Brand K, M?ller E, Page S, Gr?ner S, Lorenz M, Sadoul K, Kolanus W, Lengyel E, Gawaz MJournal of cell scienceRole of beta(3)-endonexin in the regulation of NF-kappaB-dependent expression of urokinase-type plasminogen activator receptor. J Cell Sci. 2002 Oct 15; 115(Pt 20):3879-88.J Cell Sci2002-10-15T00:00:002002Role of beta(3)-endonexin in the regulation of NF-kappaB-dependent expression of urokinase-type plasminogen activator receptor.11400328Lengyel E, Ried S, Heiss MM, J?ger C, Schmitt M, Allgayer HMethods in enzymologyRas regulation of urokinase-type plasminogen activator. Methods Enzymol. 2001; 333:105-16.Methods Enzymol2001-01-01T00:00:002001Ras regulation of urokinase-type plasminogen activator.11531282Lengyel E, Schmalfeldt B, Konik E, Sp?the K, H?rting K, Fenn A, Berger U, Fridman R, Schmitt M, Prechtel D, Kuhn WGynecologic oncologyExpression of latent matrix metalloproteinase 9 (MMP-9) predicts survival in advanced ovarian cancer. Gynecol Oncol. 2001 Aug; 82(2):291-8.Gynecol Oncol2001-08-01T00:00:002001Expression of latent matrix metalloproteinase 9 (MMP-9) predicts survival in advanced ovarian cancer.15516977Singh A, Karnoub AE, Palmby TR, Lengyel E, Sondek J, Der CJOncogeneRac1b, a tumor associated, constitutively active Rac1 splice variant, promotes cellular transformation. Oncogene. 2004 Dec 16; 23(58):9369-80.Oncogene2004-12-16T00:00:002004Rac1b, a tumor associated, constitutively active Rac1 splice variant, promotes cellular transformation.15474301Kugler MC, Gerhard M, Schnelzer A, Borzym K, Reinhardt R, Schmitt M, Lengyel EGeneIsolation and characterization of Rac1 pseudogenes (psi1Rac1-psi4Rac1) in the human genome. Gene. 2004 Oct 27; 341:189-97.Gene2004-10-27T00:00:002004Isolation and characterization of Rac1 pseudogenes (psi1Rac1-psi4Rac1) in the human genome.16757127Mell LK, Kochanski JD, Roeske JC, Haslam JJ, Mehta N, Yamada SD, Hurteau JA, Collins YC, Lengyel E, Mundt AJInternational journal of radiation oncology, biology, physicsDosimetric predictors of acute hematologic toxicity in cervical cancer patients treated with concurrent cisplatin and intensity-modulated pelvic radiotherapy. Int J Radiat Oncol Biol Phys. 2006 Dec 01; 66(5):1356-65.Int J Radiat Oncol Biol Phys2006-06-06T00:00:002006Dosimetric predictors of acute hematologic toxicity in cervical cancer patients treated with concurrent cisplatin and intensity-modulated pelvic radiotherapy.Medicine-Hematology and OncologyObstetrics and Gynecology-GeneralistsObstetrics and Gynecology-Gynecologic Oncology17049587Adams SF, Hickson JA, Hutto JY, Montag AG, Lengyel E, Yamada SDGynecologic oncologyPDGFR-alpha as a potential therapeutic target in uterine sarcomas. Gynecol Oncol. 2007 Mar; 104(3):524-8.Gynecol Oncol2006-10-17T00:00:002006PDGFR-alpha as a potential therapeutic target in uterine sarcomas.15262143Chen LM, Lengyel ER, Bethan Powell CGynecologic oncologySingle-agent pulse dactinomycin has only modest activity for methotrexate-resistant gestational trophoblastic neoplasia. Gynecol Oncol. 2004 Jul; 94(1):204-7.Gynecol Oncol2004-07-01T00:00:002004Single-agent pulse dactinomycin has only modest activity for methotrexate-resistant gestational trophoblastic neoplasia.17957144Park SM, Shell S, Radjabi AR, Schickel R, Feig C, Boyerinas B, Dinulescu DM, Lengyel E, Peter MECell cycle (Georgetown, Tex.)Let-7 prevents early cancer progression by suppressing expression of the embryonic gene HMGA2. Cell Cycle. 2007 Nov 01; 6(21):2585-90.Cell Cycle2007-08-06T00:00:002007Let-7 prevents early cancer progression by suppressing expression of the embryonic gene HMGA2.15455388Lengyel E, Prechtel D, Resau JH, Gauger K, Welk A, Lindemann K, Salanti G, Richter T, Knudsen B, Vande Woude GF, Harbeck NInternational journal of cancerC-Met overexpression in node-positive breast cancer identifies patients with poor clinical outcome independent of Her2/neu. Int J Cancer. 2005 Feb 10; 113(4):678-82.Int J Cancer2005-02-10T00:00:002005C-Met overexpression in node-positive breast cancer identifies patients with poor clinical outcome independent of Her2/neu.17510314Leupold JH, Asangani I, Maurer GD, Lengyel E, Post S, Allgayer HMolecular cancer research : MCRSrc induces urokinase receptor gene expression and invasion/intravasation via activator protein-1/p-c-Jun in colorectal cancer. Mol Cancer Res. 2007 May; 5(5):485-96.Mol Cancer Res2007-05-01T00:00:002007Src induces urokinase receptor gene expression and invasion/intravasation via activator protein-1/p-c-Jun in colorectal cancer.18823649Terplan M, Temkin S, Tergas A, Lengyel EGynecologic oncologyDoes equal treatment yield equal outcomes? The impact of race on survival in epithelial ovarian cancer. Gynecol Oncol. 2008 Nov; 111(2):173-8.Gynecol Oncol2008-09-26T00:00:002008Does equal treatment yield equal outcomes? The impact of race on survival in epithelial ovarian cancer.18554701Onujiogu N, Lengyel E, Yamada SDGynecologic oncologyReversible posterior leukoencephalopathy syndrome following intravenous paclitaxel and intraperitoneal cisplatin chemotherapy for fallopian tube cancer. Gynecol Oncol. 2008 Dec; 111(3):537-9.Gynecol Oncol2008-06-13T00:00:002008Reversible posterior leukoencephalopathy syndrome following intravenous paclitaxel and intraperitoneal cisplatin chemotherapy for fallopian tube cancer.18048360Radjabi AR, Sawada K, Jagadeeswaran S, Eichbichler A, Kenny HA, Montag A, Bruno K, Lengyel EThe Journal of biological chemistryThrombin induces tumor invasion through the induction and association of matrix metalloproteinase-9 and beta1-integrin on the cell surface. J Biol Chem. 2008 Feb 01; 283(5):2822-34.J Biol Chem2007-11-29T00:00:002007Thrombin induces tumor invasion through the induction and association of matrix metalloproteinase-9 and beta1-integrin on the cell surface.18340378Kenny HA, Kaur S, Coussens LM, Lengyel EThe Journal of clinical investigationThe initial steps of ovarian cancer cell metastasis are mediated by MMP-2 cleavage of vitronectin and fibronectin. J Clin Invest. 2008 Apr; 118(4):1367-79.J Clin Invest2008-04-01T00:00:002008The initial steps of ovarian cancer cell metastasis are mediated by MMP-2 cleavage of vitronectin and fibronectin.Authorship 1455181233818123Lindau ST, Makelarski JA, Boyd K, Doyle KE, Haider S, Kumar S, Lee NK, Pinkerton E, Tobin M, Vu M, Wroblewski KE, Lengyel EJournal of women's health (2002)Change in Health-Related Socioeconomic Risk Factors and Mental Health During the Early Phase of the COVID-19 Pandemic: A National Survey of U.S. Women. J Womens Health (Larchmt). 2021 04; 30(4):502-513.J Womens Health (Larchmt)2021-04-05T00:00:002021Change in Health-Related Socioeconomic Risk Factors and Mental Health During the Early Phase of the COVID-19 Pandemic: A National Survey of U.S. Women.20072648Zillhardt M, Christensen JG, Lengyel ENeoplasia (New York, N.Y.)An orally available small-molecule inhibitor of c-Met, PF-2341066, reduces tumor burden and metastasis in a preclinical model of ovarian cancer metastasis. Neoplasia. 2010 Jan; 12(1):1-10.Neoplasia2010-01-01T00:00:002010An orally available small-molecule inhibitor of c-Met, PF-2341066, reduces tumor burden and metastasis in a preclinical model of ovarian cancer metastasis.19221481Kenny HA, Lengyel ECell cycle (Georgetown, Tex.)MMP-2 functions as an early response protein in ovarian cancer metastasis. Cell Cycle. 2009 Mar 01; 8(5):683-8.Cell Cycle2009-03-01T00:00:002009MMP-2 functions as an early response protein in ovarian cancer metastasis.16361535Schewe DM, Biller T, Maurer G, Asangani IA, Leupold JH, Lengyel ER, Post S, Allgayer HClinical cancer research : an official journal of the American Association for Cancer ResearchCombination analysis of activator protein-1 family members, Sp1 and an activator protein-2alpha-related factor binding to different regions of the urokinase receptor gene in resected colorectal cancers. Clin Cancer Res. 2005 Dec 15; 11(24 Pt 1):8538-48.Clin Cancer Res2005-12-15T00:00:002005Combination analysis of activator protein-1 family members, Sp1 and an activator protein-2alpha-related factor binding to different regions of the urokinase receptor gene in resected colorectal cancers.19737983Romero IL, Gordon IO, Jagadeeswaran S, Mui KL, Lee WS, Dinulescu DM, Krausz TN, Kim HH, Gilliam ML, Lengyel ECancer prevention research (Philadelphia, Pa.)Effects of oral contraceptives or a gonadotropin-releasing hormone agonist on ovarian carcinogenesis in genetically engineered mice. Cancer Prev Res (Phila). 2009 Sep; 2(9):792-9.Cancer Prev Res (Phila)2009-09-08T00:00:002009Effects of oral contraceptives or a gonadotropin-releasing hormone agonist on ovarian carcinogenesis in genetically engineered mice.20505730Chen L, Park SM, Tumanov AV, Hau A, Sawada K, Feig C, Turner JR, Fu YX, Romero IL, Lengyel E, Peter MENatureCD95 promotes tumour growth. Nature. 2010 May 27; 465(7297):492-6.Nature2010-05-27T00:00:002010CD95 promotes tumour growth.17308108Sawada K, Radjabi AR, Shinomiya N, Kistner E, Kenny H, Becker AR, Turkyilmaz MA, Salgia R, Yamada SD, Vande Woude GF, Tretiakova MS, Lengyel ECancer researchc-Met overexpression is a prognostic factor in ovarian cancer and an effective target for inhibition of peritoneal dissemination and invasion. Cancer Res. 2007 Feb 15; 67(4):1670-9.Cancer Res2007-02-15T00:00:002007c-Met overexpression is a prognostic factor in ovarian cancer and an effective target for inhibition of peritoneal dissemination and invasion.21276608Bell-McGuinn KM, Matthews CM, Ho SN, Barve M, Gilbert L, Penson RT, Lengyel E, Palaparthy R, Gilder K, Vassos A, McAuliffe W, Weymer S, Barton J, Schilder RJGynecologic oncologyA phase II, single-arm study of the anti-a5ß1 integrin antibody volociximab as monotherapy in patients with platinum-resistant advanced epithelial ovarian or primary peritoneal cancer. Gynecol Oncol. 2011 May 01; 121(2):273-9.Gynecol Oncol2011-01-26T00:00:002011A phase II, single-arm study of the anti-a5ß1 integrin antibody volociximab as monotherapy in patients with platinum-resistant advanced epithelial ovarian or primary peritoneal cancer.Authorship 14640618337909Lengyel EZeitschrift fur GerontologieTwenty-year longitudinal study on aged people in Budapest. Z Gerontol. 1993 May-Jun; 26(3):156-62.Z Gerontol1993-05-01T00:00:001993Twenty-year longitudinal study on aged people in Budapest.17600087Shell S, Park SM, Radjabi AR, Schickel R, Kistner EO, Jewell DA, Feig C, Lengyel E, Peter MEProceedings of the National Academy of Sciences of the United States of AmericaLet-7 expression defines two differentiation stages of cancer. Proc Natl Acad Sci U S A. 2007 Jul 03; 104(27):11400-5.Proc Natl Acad Sci U S A2007-06-28T00:00:002007Let-7 expression defines two differentiation stages of cancer.21340784Muehlenweg B, Schnelzer A, Türkmen B, Lengyel E, Reuning U, Graeff H, Schmitt M, Magdolen VMethods in molecular medicineRFLP Molecular Analysis of the Urokinase-Type Plasminogen Activator Gene. Methods Mol Med. 2001; 39:299-306.Methods Mol Med2001-01-01T00:00:002001RFLP Molecular Analysis of the Urokinase-Type Plasminogen Activator Gene.21618519Boyerinas B, Park SM, Murmann AE, Gwin K, Montag AG, Zillhardt M, Hua YJ, Lengyel E, Peter MEInternational journal of cancerLet-7 modulates acquired resistance of ovarian cancer to Taxanes via IMP-1-mediated stabilization of multidrug resistance 1. Int J Cancer. 2012 Apr 15; 130(8):1787-97.Int J Cancer2011-08-16T00:00:002011Let-7 modulates acquired resistance of ovarian cancer to Taxanes via IMP-1-mediated stabilization of multidrug resistance 1.Authorship 1464181333964209Cui C, Chakraborty K, Tang XA, Zhou G, Schoenfelt KQ, Becker KM, Hoffman A, Chang YF, Blank A, Reardon CA, Kenny HA, Vaisar T, Lengyel E, Greene G, Becker LCellNeutrophil elastase selectively kills cancer cells and attenuates tumorigenesis. Cell. 2021 06 10; 184(12):3163-3177.e21.Cell2021-05-07T00:00:002021Neutrophil elastase selectively kills cancer cells and attenuates tumorigenesis.18381440Sawada K, Mitra AK, Radjabi AR, Bhaskar V, Kistner EO, Tretiakova M, Jagadeeswaran S, Montag A, Becker A, Kenny HA, Peter ME, Ramakrishnan V, Yamada SD, Lengyel ECancer researchLoss of E-cadherin promotes ovarian cancer metastasis via alpha 5-integrin, which is a therapeutic target. Cancer Res. 2008 Apr 01; 68(7):2329-39.Cancer Res2008-04-01T00:00:002008Loss of E-cadherin promotes ovarian cancer metastasis via alpha 5-integrin, which is a therapeutic target.D009362Disorders26910560.715996Neoplasm Metastasis21119598Mitra AK, Sawada K, Tiwari P, Mui K, Gwin K, Lengyel EOncogeneLigand-independent activation of c-Met by fibronectin and a(5)ß(1)-integrin regulates ovarian cancer invasion and metastasis. Oncogene. 2011 Mar 31; 30(13):1566-76.Oncogene2010-11-29T00:00:002010Ligand-independent activation of c-Met by fibronectin and a(5)ß(1)-integrin regulates ovarian cancer invasion and metastasis.21551255Zillhardt M, Park SM, Romero IL, Sawada K, Montag A, Krausz T, Yamada SD, Peter ME, Lengyel EClinical cancer research : an official journal of the American Association for Cancer ResearchForetinib (GSK1363089), an orally available multikinase inhibitor of c-Met and VEGFR-2, blocks proliferation, induces anoikis, and impairs ovarian cancer metastasis. Clin Cancer Res. 2011 Jun 15; 17(12):4042-51.Clin Cancer Res2011-05-06T00:00:002011Foretinib (GSK1363089), an orally available multikinase inhibitor of c-Met and VEGFR-2, blocks proliferation, induces anoikis, and impairs ovarian cancer metastasis.20036708Ko SY, Lengyel E, Naora HMolecular and cellular endocrinologyThe Müllerian HOXA10 gene promotes growth of ovarian surface epithelial cells by stimulating epithelial-stromal interactions. Mol Cell Endocrinol. 2010 Apr 12; 317(1-2):112-9.Mol Cell Endocrinol2009-12-29T00:00:002009The Müllerian HOXA10 gene promotes growth of ovarian surface epithelial cells by stimulating epithelial-stromal interactions.21682576Buell-Gutbrod R, Ivanovic M, Montag A, Lengyel E, Fadare O, Gwin KPediatric and developmental pathology : the official journal of the Society for Pediatric Pathology and the Paediatric Pathology SocietyFOXL2 and SOX9 distinguish the lineage of the sex cord-stromal cells in gonadoblastomas. Pediatr Dev Pathol. 2011 Sep-Oct; 14(5):391-5.Pediatr Dev Pathol2011-06-17T00:00:002011FOXL2 and SOX9 distinguish the lineage of the sex cord-stromal cells in gonadoblastomas.18836657Lindemann K, Harbeck N, Lengyel E, Resau JHTheScientificWorldJournalA special key for unlocking the door to targeted therapies of breast cancer. ScientificWorldJournal. 2008 Sep 21; 8:905-8.ScientificWorldJournal2008-09-21T00:00:002008A special key for unlocking the door to targeted therapies of breast cancer.D017667Anatomy701550.889726Adipocytes21996264Romero IL, Lee W, Mitra AK, Gordon IO, Zhao Y, Leonhardt P, Penicka CV, Mui KL, Krausz TN, Greene GL, Lengyel EGynecologic oncologyThe effects of 17ß-estradiol and a selective estrogen receptor modulator, bazedoxifene, on ovarian carcinogenesis. Gynecol Oncol. 2012 Jan; 124(1):134-41.Gynecol Oncol2011-10-11T00:00:002011The effects of 17ß-estradiol and a selective estrogen receptor modulator, bazedoxifene, on ovarian carcinogenesis.22037646Nieman KM, Kenny HA, Penicka CV, Ladanyi A, Buell-Gutbrod R, Zillhardt MR, Romero IL, Carey MS, Mills GB, Hotamisligil GS, Yamada SD, Peter ME, Gwin K, Lengyel ENature medicineAdipocytes promote ovarian cancer metastasis and provide energy for rapid tumor growth. Nat Med. 2011 Oct 30; 17(11):1498-503.Nat Med2011-10-30T00:00:002011Adipocytes promote ovarian cancer metastasis and provide energy for rapid tumor growth.Authorship 1477328Authorship 147886534224372Patel M, Wang Y, Bartom ET, Dhir R, Nephew KP, Matei D, Murmann AE, Lengyel E, Peter MECancer researchThe Ratio of Toxic-to-Nontoxic miRNAs Predicts Platinum Sensitivity in Ovarian Cancer. Cancer Res. 2021 08 01; 81(15):3985-4000.Cancer Res2021-06-15T00:00:002021The Ratio of Toxic-to-Nontoxic miRNAs Predicts Platinum Sensitivity in Ovarian Cancer.34201616Eckert MA, Orozco C, Xiao J, Javellana M, Lengyel ECancersThe Effects of Chemotherapeutics on the Ovarian Cancer Microenvironment. Cancers (Basel). 2021 Jun 23; 13(13).Cancers (Basel)2021-06-23T00:00:002021The Effects of Chemotherapeutics on the Ovarian Cancer Microenvironment.19808644Kaur S, Kenny HA, Jagadeeswaran S, Zillhardt MR, Montag AG, Kistner E, Yamada SD, Mitra AK, Lengyel EThe American journal of pathology{beta}3-integrin expression on tumor cells inhibits tumor progression, reduces metastasis, and is associated with a favorable prognosis in patients with ovarian cancer. Am J Pathol. 2009 Nov; 175(5):2184-96.Am J Pathol2009-10-01T00:00:002009{beta}3-integrin expression on tumor cells inhibits tumor progression, reduces metastasis, and is associated with a favorable prognosis in patients with ovarian cancer.21149615Kenny HA, Leonhardt P, Ladanyi A, Yamada SD, Montag A, Im HK, Jagadeeswaran S, Shaw DE, Mazar AP, Lengyel EClinical cancer research : an official journal of the American Association for Cancer ResearchTargeting the urokinase plasminogen activator receptor inhibits ovarian cancer metastasis. Clin Cancer Res. 2011 Feb 01; 17(3):459-71.Clin Cancer Res2010-12-13T00:00:002010Targeting the urokinase plasminogen activator receptor inhibits ovarian cancer metastasis.21366131Temkin SM, Turner JR, Lengyel ERThe Journal of reproductive medicineAcute inflammatory reaction following placement of sodium hyaluronate-carboxymethylcellulose barrier in a young woman undergoing gynecologic surgery: a case report. J Reprod Med. 2011 Jan-Feb; 56(1-2):71-4.J Reprod Med2011-01-01T00:00:002011Acute inflammatory reaction following placement of sodium hyaluronate-carboxymethylcellulose barrier in a young woman undergoing gynecologic surgery: a case report.21941283Vaughan S, Coward JI, Bast RC, Berchuck A, Berek JS, Brenton JD, Coukos G, Crum CC, Drapkin R, Etemadmoghadam D, Friedlander M, Gabra H, Kaye SB, Lord CJ, Lengyel E, Levine DA, McNeish IA, Menon U, Mills GB, Nephew KP, Oza AM, Sood AK, Stronach EA, Walczak H, Bowtell DD, Balkwill FRNature reviews. CancerRethinking ovarian cancer: recommendations for improving outcomes. Nat Rev Cancer. 2011 Sep 23; 11(10):719-25.Nat Rev Cancer2011-09-23T00:00:002011Rethinking ovarian cancer: recommendations for improving outcomes.22835717Tergas AI, Buell-Gutbrod R, Gwin K, Kocherginsky M, Temkin SM, Fefferman A, Lengyel E, Yamada SDGynecologic oncologyClinico-pathologic comparison of type II endometrial cancers based on tamoxifen exposure. Gynecol Oncol. 2012 Nov; 127(2):316-20.Gynecol Oncol2012-07-24T00:00:002012Clinico-pathologic comparison of type II endometrial cancers based on tamoxifen exposure.7559439Lengyel E, Stepp E, Gum R, Boyd DThe Journal of biological chemistryInvolvement of a mitogen-activated protein kinase signaling pathway in the regulation of urokinase promoter activity by c-Ha-ras. J Biol Chem. 1995 Sep 29; 270(39):23007-12.J Biol Chem1995-09-29T00:00:001995Involvement of a mitogen-activated protein kinase signaling pathway in the regulation of urokinase promoter activity by c-Ha-ras.Authorship 14908714Authorship 1490971134439084Kenny HA, Hart PC, Kordylewicz K, Lal M, Shen M, Kara B, Chen YJ, Grassl N, Alharbi Y, Pattnaik BR, Watters KM, Patankar MS, Ferrer M, Lengyel ECancersThe Natural Product ß-Escin Targets Cancer and Stromal Cells of the Tumor Microenvironment to Inhibit Ovarian Cancer Metastasis. Cancers (Basel). 2021 Aug 04; 13(16).Cancers (Basel)2021-08-04T00:00:002021The Natural Product ß-Escin Targets Cancer and Stromal Cells of the Tumor Microenvironment to Inhibit Ovarian Cancer Metastasis.34452747Somasegar S, Weiss AS, Norquist BM, Khasnavis N, Radke M, Manhardt E, Pennil C, Pennington KP, Eckert MA, Chryplewicz A, Lengyel E, Swisher EMGynecologic oncologyGermline mutations in Black patients with ovarian, fallopian tube and primary peritoneal carcinomas. Gynecol Oncol. 2021 10; 163(1):130-133.Gynecol Oncol2021-08-24T00:00:002021Germline mutations in Black patients with ovarian, fallopian tube and primary peritoneal carcinomas.22013555Kenny HA, Nieman KM, Mitra AK, Lengyel ECancer discoveryThe first line of intra-abdominal metastatic attack: breaching the mesothelial cell layer. Cancer Discov. 2011 Jul; 1(2):100-2.Cancer Discov2011-07-01T00:00:002011The first line of intra-abdominal metastatic attack: breaching the mesothelial cell layer.7653995Gum R, Wang SW, Lengyel E, Yu D, Hung MC, Juarez J, Boyd DAnticancer researchUp-regulation of urokinase-type plasminogen activator expression by the HER2/neu proto-oncogene. Anticancer Res. 1995 Jul-Aug; 15(4):1167-72.Anticancer Res1995-07-01T00:00:001995Up-regulation of urokinase-type plasminogen activator expression by the HER2/neu proto-oncogene.17311534Lengyel E, Sawada K, Salgia RCurrent molecular medicineTyrosine kinase mutations in human cancer. Curr Mol Med. 2007 Feb; 7(1):77-84.Curr Mol Med2007-02-01T00:00:002007Tyrosine kinase mutations in human cancer.17546601Kenny HA, Krausz T, Yamada SD, Lengyel EInternational journal of cancerUse of a novel 3D culture model to elucidate the role of mesothelial cells, fibroblasts and extra-cellular matrices on adhesion and invasion of ovarian cancer cells to the omentum. Int J Cancer. 2007 Oct 01; 121(7):1463-72.Int J Cancer2007-10-01T00:00:002007Use of a novel 3D culture model to elucidate the role of mesothelial cells, fibroblasts and extra-cellular matrices on adhesion and invasion of ovarian cancer cells to the omentum.7505531Schaller G, Lengyel E, Pantel K, Hardt W, Mischke DAmerican journal of obstetrics and gynecologyKeratin expression reveals mosaic differentiation in vaginal epithelium. Am J Obstet Gynecol. 1993 Dec; 169(6):1603-7.Am J Obstet Gynecol1993-12-01T00:00:001993Keratin expression reveals mosaic differentiation in vaginal epithelium.18381893Park SM, Gaur AB, Lengyel E, Peter MEGenes & developmentThe miR-200 family determines the epithelial phenotype of cancer cells by targeting the E-cadherin repressors ZEB1 and ZEB2. Genes Dev. 2008 Apr 01; 22(7):894-907.Genes Dev2008-04-01T00:00:002008The miR-200 family determines the epithelial phenotype of cancer cells by targeting the E-cadherin repressors ZEB1 and ZEB2.7626664Lengyel E, Klostergaard J, Boyd DBiochimica et biophysica actaStimulation of urokinase expression by TNF-alpha requires the activation of binding sites for the AP-1 and PEA3 transcription factors. Biochim Biophys Acta. 1995 Jul 20; 1268(1):65-72.Biochim Biophys Acta1995-07-20T00:00:001995Stimulation of urokinase expression by TNF-alpha requires the activation of binding sites for the AP-1 and PEA3 transcription factors.7850814Lengyel E, Gum R, Juarez J, Clayman G, Seiki M, Sato H, Boyd DCancer researchInduction of M(r) 92,000 type IV collagenase expression in a squamous cell carcinoma cell line by fibroblasts. Cancer Res. 1995 Feb 15; 55(4):963-7.Cancer Res1995-02-15T00:00:001995Induction of M(r) 92,000 type IV collagenase expression in a squamous cell carcinoma cell line by fibroblasts.19643405Banz C, Ungethuem U, Kuban RJ, Diedrich K, Lengyel E, Hornung DFertility and sterilityThe molecular signature of endometriosis-associated endometrioid ovarian cancer differs significantly from endometriosis-independent endometrioid ovarian cancer. Fertil Steril. 2010 Sep; 94(4):1212-1217.Fertil Steril2009-07-30T00:00:002009The molecular signature of endometriosis-associated endometrioid ovarian cancer differs significantly from endometriosis-independent endometrioid ovarian cancer.20651229Lengyel EThe American journal of pathologyOvarian cancer development and metastasis. Am J Pathol. 2010 Sep; 177(3):1053-64.Am J Pathol2010-07-22T00:00:002010Ovarian cancer development and metastasis.8631874Gum R, Lengyel E, Juarez J, Chen JH, Sato H, Seiki M, Boyd DThe Journal of biological chemistryStimulation of 92-kDa gelatinase B promoter activity by ras is mitogen-activated protein kinase kinase 1-independent and requires multiple transcription factor binding sites including closely spaced PEA3/ets and AP-1 sequences. J Biol Chem. 1996 May 03; 271(18):10672-80.J Biol Chem1996-05-03T00:00:001996Stimulation of 92-kDa gelatinase B promoter activity by ras is mitogen-activated protein kinase kinase 1-independent and requires multiple transcription factor binding sites including closely spaced PEA3/ets and AP-1 sequences.21168200Bishop EA, Lengyel ER, Yamada SD, Montag A, Temkin SMGynecologic oncologyThe expression of hepatocyte growth factor (HGF) and c-Met in uterine serous carcinoma. Gynecol Oncol. 2011 Apr; 121(1):218-23.Gynecol Oncol2010-12-17T00:00:002010The expression of hepatocyte growth factor (HGF) and c-Met in uterine serous carcinoma.Authorship 150361534651237Kumar S, Lee NK, Pinkerton E, Wroblewski KE, Lengyel E, Tobin MArchives of women's mental healthResilience: a mediator of the negative effects of pandemic-related stress on women's mental health in the USA. Arch Womens Ment Health. 2022 02; 25(1):137-146.Arch Womens Ment Health2021-10-14T00:00:002021Resilience: a mediator of the negative effects of pandemic-related stress on women's mental health in the USA.22945634Ko SY, Barengo N, Ladanyi A, Lee JS, Marini F, Lengyel E, Naora HThe Journal of clinical investigationHOXA9 promotes ovarian cancer growth by stimulating cancer-associated fibroblasts. J Clin Invest. 2012 Oct; 122(10):3603-17.J Clin Invest2012-09-04T00:00:002012HOXA9 promotes ovarian cancer growth by stimulating cancer-associated fibroblasts.11121811Dickfeld T, Lengyel E, May AE, Massberg S, Brand K, Page S, Thielen C, Langenbrink K, Gawaz MCardiovascular researchTransient interaction of activated platelets with endothelial cells induces expression of monocyte-chemoattractant protein-1 via a p38 mitogen-activated protein kinase mediated pathway. Implications for atherogenesis. Cardiovasc Res. 2001 Jan; 49(1):189-99.Cardiovasc Res2001-01-01T00:00:002001Transient interaction of activated platelets with endothelial cells induces expression of monocyte-chemoattractant protein-1 via a p38 mitogen-activated protein kinase mediated pathway. Implications for atherogenesis.17593080Lindemann K, Resau J, Nährig J, Kort E, Leeser B, Annecke K, Welk A, Schäfer J, Vande Woude GF, Lengyel E, Harbeck NHistopathologyDifferential expression of c-Met, its ligand HGF/SF and HER2/neu in DCIS and adjacent normal breast tissue. Histopathology. 2007 Jul; 51(1):54-62.Histopathology2007-07-01T00:00:002007Differential expression of c-Met, its ligand HGF/SF and HER2/neu in DCIS and adjacent normal breast tissue.18815565Knudsen BS, Zhao P, Resau J, Cottingham S, Gherardi E, Xu E, Berghuis B, Daugherty J, Grabinski T, Toro J, Giambernardi T, Skinner RS, Gross M, Hudson E, Kort E, Lengyel E, Ventura A, West RA, Xie Q, Hay R, Vande Woude G, Cao BApplied immunohistochemistry & molecular morphology : AIMMA novel multipurpose monoclonal antibody for evaluating human c-Met expression in preclinical and clinical settings. Appl Immunohistochem Mol Morphol. 2009 Jan; 17(1):57-67.Appl Immunohistochem Mol Morphol2009-01-01T00:00:002009A novel multipurpose monoclonal antibody for evaluating human c-Met expression in preclinical and clinical settings.19497979Arimoto-Ishida E, Sakata M, Sawada K, Nakayama M, Nishimoto F, Mabuchi S, Takeda T, Yamamoto T, Isobe A, Okamoto Y, Lengyel E, Suehara N, Morishige K, Kimura TEndocrinologyUp-regulation of alpha5-integrin by E-cadherin loss in hypoxia and its key role in the migration of extravillous trophoblast cells during early implantation. Endocrinology. 2009 Sep; 150(9):4306-15.Endocrinology2009-06-04T00:00:002009Up-regulation of alpha5-integrin by E-cadherin loss in hypoxia and its key role in the migration of extravillous trophoblast cells during early implantation.19584084Deplazes J, Fuchs M, Rauser S, Genth H, Lengyel E, Busch R, Luber BHuman molecular geneticsRac1 and Rho contribute to the migratory and invasive phenotype associated with somatic E-cadherin mutation. Hum Mol Genet. 2009 Oct 01; 18(19):3632-44.Hum Mol Genet2009-07-07T00:00:002009Rac1 and Rho contribute to the migratory and invasive phenotype associated with somatic E-cadherin mutation.19763444Kenny HA, Dogan S, Zillhardt M, K Mitra A, Yamada SD, Krausz T, Lengyel ECancer treatment and researchOrganotypic models of metastasis: A three-dimensional culture mimicking the human peritoneum and omentum for the study of the early steps of ovarian cancer metastasis. Cancer Treat Res. 2009; 149:335-51.Cancer Treat Res2009-01-01T00:00:002009Organotypic models of metastasis: A three-dimensional culture mimicking the human peritoneum and omentum for the study of the early steps of ovarian cancer metastasis.D010534Disorders721750.873369Peritoneal Neoplasms22183212Romero IL, McCormick A, McEwen KA, Park S, Karrison T, Yamada SD, Pannain S, Lengyel EObstetrics and gynecologyRelationship of type II diabetes and metformin use to ovarian cancer progression, survival, and chemosensitivity. Obstet Gynecol. 2012 Jan; 119(1):61-7.Obstet Gynecol2012-01-01T00:00:002012Relationship of type II diabetes and metformin use to ovarian cancer progression, survival, and chemosensitivity.Authorship 1509051434737212Javellana M, Eckert MA, Heide J, Zawieracz K, Weigert M, Ashley S, Stock E, Chapel D, Huang L, Yamada SD, Ahmed AA, Lastra RR, Chen M, Lengyel ECancer researchNeoadjuvant Chemotherapy Induces Genomic and Transcriptomic Changes in Ovarian Cancer. Cancer Res. 2022 01 01; 82(1):169-176.Cancer Res2021-11-04T00:00:002021Neoadjuvant Chemotherapy Induces Genomic and Transcriptomic Changes in Ovarian Cancer.Authorship 153170935201895Javellana M, Hlubocky FJ, Somasegar S, Sorkin M, Kurnit KC, Jani I, Stock E, Mills K, Lengyel E, Lee NKJCO oncology practiceResilience in the Face of Pandemic: The Impact of COVID-19 on the Psychologic Morbidity and Health-Related Quality of Life Among Women With Ovarian Cancer. JCO Oncol Pract. 2022 06; 18(6):e948-e957.JCO Oncol Pract2022-02-24T00:00:002022Resilience in the Face of Pandemic: The Impact of COVID-19 on the Psychologic Morbidity and Health-Related Quality of Life Among Women With Ovarian Cancer.Authorship 154533635519002Kurnit KC, Steiner M, Lastra RR, Weroha SJ, Cursio J, Lengyel E, Fleming GF, Conzen SDGynecologic oncology reportsHigh glucocorticoid receptor expression in the sarcomatous versus carcinomatous elements of Mullerian carcinosarcomas. Gynecol Oncol Rep. 2022 Jun; 41:100987.Gynecol Oncol Rep2022-04-27T00:00:002022High glucocorticoid receptor expression in the sarcomatous versus carcinomatous elements of Mullerian carcinosarcomas.Authorship 1548991335590073Mund A, Coscia F, Kriston A, Hollandi R, Kovács F, Brunner AD, Migh E, Schweizer L, Santos A, Bzorek M, Naimy S, Rahbek-Gjerdrum LM, Dyring-Andersen B, Bulkescher J, Lukas C, Eckert MA, Lengyel E, Gnann C, Lundberg E, Horvath P, Mann MNature biotechnologyDeep Visual Proteomics defines single-cell identity and heterogeneity. Nat Biotechnol. 2022 08; 40(8):1231-1240.Nat Biotechnol2022-05-19T00:00:002022Deep Visual Proteomics defines single-cell identity and heterogeneity.Authorship 15528728341162Beregi E, Lengyel E, Regius OMethods of information in medicinePhysiological age-related changes: cross-sectional and longitudinal studies. Methods Inf Med. 1993 Apr; 32(3):252-4.Methods Inf Med1993-04-01T00:00:001993Physiological age-related changes: cross-sectional and longitudinal studies.35941408Mukherjee A, Bilecz AJ, Lengyel ECancer metastasis reviewsThe adipocyte microenvironment and cancer. Cancer Metastasis Rev. 2022 09; 41(3):575-587.Cancer Metastasis Rev2022-08-08T00:00:002022The adipocyte microenvironment and cancer.Authorship 6331016Authorship 633118Authorship 633127Authorship 633133Authorship 633143Authorship 6331510Authorship 633161Authorship 633172Authorship 633184Authorship 63319625202979Kenny HA, Chiang CY, White EA, Schryver EM, Habis M, Romero IL, Ladanyi A, Penicka CV, George J, Matlin K, Montag A, Wroblewski K, Yamada SD, Mazar AP, Bowtell D, Lengyel EThe Journal of clinical investigationMesothelial cells promote early ovarian cancer metastasis through fibronectin secretion. J Clin Invest. 2014 Oct; 124(10):4614-28.J Clin Invest2014-09-09T00:00:002014Mesothelial cells promote early ovarian cancer metastasis through fibronectin secretion.24332016Ko SY, Ladanyi A, Lengyel E, Naora HThe American journal of pathologyExpression of the homeobox gene HOXA9 in ovarian cancer induces peritoneal macrophages to acquire an M2 tumor-promoting phenotype. Am J Pathol. 2014 Jan; 184(1):271-81.Am J Pathol2014-01-01T00:00:002014Expression of the homeobox gene HOXA9 in ovarian cancer induces peritoneal macrophages to acquire an M2 tumor-promoting phenotype.23500888Nieman KM, Romero IL, Van Houten B, Lengyel EBiochimica et biophysica actaAdipose tissue and adipocytes support tumorigenesis and metastasis. Biochim Biophys Acta. 2013 Oct; 1831(10):1533-41.Biochim Biophys Acta2013-03-14T00:00:002013Adipose tissue and adipocytes support tumorigenesis and metastasis.24989588Hunn J, Tenney M, Bishop E, Moore K, Tergas A, Lengyel E, Lee N, Yamada SGynecologic oncologyUtility of routine surveillance methods in detecting recurrence in high grade endometrial cancer patients. Gynecol Oncol. 2012 Oct; 127(1 Suppl):S5-6.Gynecol Oncol2012-10-01T00:00:002012Utility of routine surveillance methods in detecting recurrence in high grade endometrial cancer patients.25034878White EA, Kenny HA, Lengyel EAdvanced drug delivery reviewsThree-dimensional modeling of ovarian cancer. Adv Drug Deliv Rev. 2014 Dec 15; 79-80:184-92.Adv Drug Deliv Rev2014-07-14T00:00:002014Three-dimensional modeling of ovarian cancer.24061648Zhang Y, Kenny HA, Swindell EP, Mitra AK, Hankins PL, Ahn RW, Gwin K, Mazar AP, O'Halloran TV, Lengyel EMolecular cancer therapeuticsUrokinase plasminogen activator system-targeted delivery of nanobins as a novel ovarian cancer therapy. Mol Cancer Ther. 2013 Dec; 12(12):2628-39.Mol Cancer Ther2013-09-23T00:00:002013Urokinase plasminogen activator system-targeted delivery of nanobins as a novel ovarian cancer therapy.23934194Lengyel E, Burdette JE, Kenny HA, Matei D, Pilrose J, Haluska P, Nephew KP, Hales DB, Stack MSOncogeneEpithelial ovarian cancer experimental models. Oncogene. 2014 Jul 10; 33(28):3619-33.Oncogene2013-08-12T00:00:002013Epithelial ovarian cancer experimental models.25174399King ML, Lindberg ME, Stodden GR, Okuda H, Ebers SD, Johnson A, Montag A, Lengyel E, MacLean Ii JA, Hayashi KOncogeneWNT7A/ß-catenin signaling induces FGF1 and influences sensitivity to niclosamide in ovarian cancer. Oncogene. 2015 Jun; 34(26):3452-62.Oncogene2014-09-01T00:00:002014WNT7A/ß-catenin signaling induces FGF1 and influences sensitivity to niclosamide in ovarian cancer.25118694Habis M, Wroblewski K, Bradaric M, Ismail N, Yamada SD, Litchfield L, Lengyel E, Romero ILPloS oneStatin therapy is associated with improved survival in patients with non-serous-papillary epithelial ovarian cancer: a retrospective cohort analysis. PLoS One. 2014; 9(8):e104521.PLoS One2014-08-13T00:00:002014Statin therapy is associated with improved survival in patients with non-serous-papillary epithelial ovarian cancer: a retrospective cohort analysis.23926600Landen CN, Lengyel EGynecologic oncologySummary of the 2013 American Association for Cancer Research (AACR) Annual Meeting. Gynecol Oncol. 2013 Jul; 130(1):6-8.Gynecol Oncol2013-07-01T00:00:002013Summary of the 2013 American Association for Cancer Research (AACR) Annual Meeting.Authorship 1594422Authorship 1585463Authorship 1589861Authorship 159564236139624Nakad Borrego S, Lengyel E, Kurnit KCCancersMolecular Characterizations of Gynecologic Carcinosarcomas: A Focus on the Immune Microenvironment. Cancers (Basel). 2022 Sep 14; 14(18).Cancers (Basel)2022-09-14T00:00:002022Molecular Characterizations of Gynecologic Carcinosarcomas: A Focus on the Immune Microenvironment.36114807Yoeli-Bik R, Lengyel E, Mills KA, Abramowicz JSJournal of ultrasound in medicine : official journal of the American Institute of Ultrasound in MedicineOvarian Masses: The Value of Acoustic Shadowing on Ultrasound Examination. J Ultrasound Med. 2023 Apr; 42(4):935-945.J Ultrasound Med2022-09-17T00:00:002022Ovarian Masses: The Value of Acoustic Shadowing on Ultrasound Examination.36543131Lengyel E, Li Y, Weigert M, Zhu L, Eckart H, Javellana M, Ackroyd S, Xiao J, Olalekan S, Glass D, Iyer S, Krishnan R, Bilecz AJ, Lastra R, Chen M, Basu ACell reportsA molecular atlas of the human postmenopausal fallopian tube and ovary from single-cell RNA and ATAC sequencing. Cell Rep. 2022 12 20; 41(12):111838.Cell Rep2022-12-20T00:00:002022A molecular atlas of the human postmenopausal fallopian tube and ovary from single-cell RNA and ATAC sequencing.D059016Phenomena1404150.763796Tumor MicroenvironmentAuthorship 1605741036717463Docheva N, Heimberger S, Mueller A, Bisson C, Arenas G, Perdigao JL, Kordik A, Stewart K, Goodall P, Lengyel E, Rana SReproductive sciences (Thousand Oaks, Calif.)A Comparison of Obstetric Interventions and Outcomes Between Black and White Patients at an Urban Tertiary Medical Center. Reprod Sci. 2023 07; 30(7):2313-2323.Reprod Sci2023-01-30T00:00:002023A Comparison of Obstetric Interventions and Outcomes Between Black and White Patients at an Urban Tertiary Medical Center.Authorship 640172Authorship 64018125455733Febbraro T, Lengyel E, Romero ILGynecologic oncologyOld drug, new trick: repurposing metformin for gynecologic cancers? Gynecol Oncol. 2014 Dec; 135(3):614-21.Gynecol Oncol2014-10-23T00:00:002014Old drug, new trick: repurposing metformin for gynecologic cancers?25446664Lengyel E, Litchfield LM, Mitra AK, Nieman KM, Mukherjee A, Zhang Y, Johnson A, Bradaric M, Lee W, Romero ILAmerican journal of obstetrics and gynecologyMetformin inhibits ovarian cancer growth and increases sensitivity to paclitaxel in mouse models. Am J Obstet Gynecol. 2015 Apr; 212(4):479.e1-479.e10.Am J Obstet Gynecol2014-10-19T00:00:002014Metformin inhibits ovarian cancer growth and increases sensitivity to paclitaxel in mouse models.Authorship 161025636795484Bajwa P, Kordylewicz K, Bilecz A, Lastra RR, Wroblewski K, Rinkevich Y, Lengyel E, Kenny HAJCI insightCancer-associated mesothelial cell-derived ANGPTL4 and STC1 promote the early steps of ovarian cancer metastasis. JCI Insight. 2023 03 22; 8(6).JCI Insight2023-03-22T00:00:002023Cancer-associated mesothelial cell-derived ANGPTL4 and STC1 promote the early steps of ovarian cancer metastasis.https://cgh.uchicago.edu/page/leadershipGlobal Healthhttps://obgyn.uchicago.edu/page/section-gynecologic-oncologyGynecologic Oncology Section - Univ. of Chicagohttps://www.uchicagomedicine.org/find-a-physician/physician/olufunmilayo-i-olopadeUChicago Medicinehttps://obgyn.uchicago.edu/Univ. of Chicago OB&GYNhttp://obg.bsd.uchicago.edu/FacultyResearch/lengyellab.htmOvarian Cancer Laboratory in Chicagohttps://cancerbio.uchicago.edu/program/faculty/olufunmilayo-olopadeCancer Biologyhttps://www.uchicagomedicine.org/conditions-services/cancer/cancer-risk-preventionCancer Risk and Preventionhttps://www.uchicagomedicine.org/find-a-physician/physician/ernst-lengyelClinical Profilehttps://womanlab.org/WomanLabhttps://www.uchicagomedicine.org/conditions-services/obgyn/specialtyOB&GYN Clinical Patient information@WomanLab_Authorship 1623005Authorship 163158237128849Kelliher L, Lengyel ECancer researchUnderstanding Long-Term Survival of Patients with Ovarian Cancer-The Tumor Microenvironment Comes to the Forefront. Cancer Res. 2023 05 02; 83(9):1383-1385.Cancer Res2023-05-02T00:00:002023Understanding Long-Term Survival of Patients with Ovarian Cancer-The Tumor Microenvironment Comes to the Forefront.36973758Ko SY, Lee W, Weigert M, Jonasch E, Lengyel E, Naora HJournal of extracellular vesiclesThe glycoprotein CD147 defines miRNA-enriched extracellular vesicles that derive from cancer cells. J Extracell Vesicles. 2023 04; 12(4):e12318.J Extracell Vesicles2023-04-01T00:00:002023The glycoprotein CD147 defines miRNA-enriched extracellular vesicles that derive from cancer cells.Authorship 1636702Authorship 1643426Authorship 164175437311411Shimizu A, Lengyel ECancer cellDecoding evolutionary trajectories of ovarian cancer metastasis. Cancer Cell. 2023 06 12; 41(6):1008-1010.Cancer Cell2023-06-12T00:00:002023Decoding evolutionary trajectories of ovarian cancer metastasis.37345662Akasaka H, Lee W, Ko SY, Lengyel E, Naora HJCI insightNormal saline remodels the omentum and stimulates its receptivity for transcoelomic metastasis. JCI Insight. 2023 06 22; 8(12).JCI Insight2023-06-22T00:00:002023Normal saline remodels the omentum and stimulates its receptivity for transcoelomic metastasis.37440228Yoeli-Bik R, Longman RE, Wroblewski K, Weigert M, Abramowicz JS, Lengyel EJAMA network openDiagnostic Performance of Ultrasonography-Based Risk Models in Differentiating Between Benign and Malignant Ovarian Tumors in a US Cohort. JAMA Netw Open. 2023 Jul 03; 6(7):e2323289.JAMA Netw Open2023-07-03T00:00:002023Diagnostic Performance of Ultrasonography-Based Risk Models in Differentiating Between Benign and Malignant Ovarian Tumors in a US Cohort.MedicinePathologyUniversity of Chicago37653041Mukherjee A, Bezwada D, Greco F, Zandbergen M, Shen T, Chiang CY, Tasdemir M, Fahrmann J, Grapov D, La Frano MR, Vu HS, Faubert B, Newman JW, McDonnell LA, Nezi L, Fiehn O, DeBerardinis RJ, Lengyel ENature metabolismAdipocytes reprogram cancer cell metabolism by diverting glucose towards glycerol-3-phosphate thereby promoting metastasis. Nat Metab. 2023 09; 5(9):1563-1577.Nat Metab2023-08-31T00:00:002023Adipocytes reprogram cancer cell metabolism by diverting glucose towards glycerol-3-phosphate thereby promoting metastasis.Authorship 16592918GiniFleming0GRlDqwcF+v5hHlsaUXv9Gq0+s+oGini Fleming41.78927490000000-87.601250000000001804Fleming, GiniProfessorSeiko DianeYamadaxGZwCqwUHe35k2lgLlPt+2z5/syyp7BaZQ==Seiko Diane Yamada41.78927490000000-87.60125000000000184Yamada, Seiko DianeProfessorRaviSalgiaRavi Salgia41.78927490000000-87.601250000000001937Salgia, RaviEmeritus/Emerita, Professor17.38660.0047716724research areas7.591650.033494547coauthor of172.95225.870560similar to11180selected publicationsIrisRomeroIris Romero41.78927490000000-87.601250000000001946Romero, IrisProfessorOlufunmilayoOlopade321vBIF1GuTQkntjbwjr93A=Olufunmilayo Olopade41.78927490000000-87.601250000000001960Olopade, OlufunmilayoProfessorStacyLindauStacy Lindau41.78927490000000-87.601250000000002240Lindau, StacyProfessorRalph R.WeichselbaumxXB+DqgWEf/5hHlsaUXv9Gq0+s+oRalph R. Weichselbaum41.78927490000000-87.601250000000002521Weichselbaum, Ralph R.ProfessorHilaryKennyHilary Kenny41.78927490000000-87.601250000000002548Kenny, HilaryResearch Associate ProfessorYusukeNakamuraYusuke Nakamura41.78927490000000-87.60125000000000582Nakamura, YusukeEmeritus/Emerita, ProfessorShirley RBaronShirley R Baron41.78927490000000-87.60125000000000789Baron, Shirley RClinical AssociateLuciaSchugerLucia Schuger41.78927490000000-87.6012500000000087Schuger, LuciaPROFESSORNitaLeeNita Lee41.78927490000000-87.6012500000000095Lee, NitaAssociate ProfessorAuthorship 1683642338014221Schweizer L, Krishnan R, Shimizu A, Metousis A, Kenny H, Mendoza R, Nordmann TM, Rauch S, Kelliher L, Heide J, Rosenberger FA, Bilecz A, Borrego SN, Strauss MT, Thielert M, Rodriguez E, Müller-Reif JB, Chen M, Yamada SD, Mund A, Lastra RR, Mann M, Lengyel EmedRxiv : the preprint server for health sciencesSpatial proteo-transcriptomic profiling reveals the molecular landscape of borderline ovarian tumors and their invasive progression. medRxiv. 2023 Nov 13.medRxiv2023-11-13T00:00:002023Spatial proteo-transcriptomic profiling reveals the molecular landscape of borderline ovarian tumors and their invasive progression.Authorship 1697061138262243Weigert M, Cui XL, West-Szymanski D, Yu X, Bilecz AJ, Zhang Z, Dhir R, Kehoe M, Zhang W, He C, Lengyel EGynecologic oncology5-Hydroxymethylcytosine signals in serum are a predictor of chemoresistance in high-grade serous ovarian cancer. Gynecol Oncol. 2024 Jan 22; 182:82-90.Gynecol Oncol2024-01-22T00:00:0020245-Hydroxymethylcytosine signals in serum are a predictor of chemoresistance in high-grade serous ovarian cancer.true1Emeritus/Emerita, ProfessorEmeritus/Emerita, Professortrue1Emeritus/Emerita, ProfessorEmeritus/Emerita, Professortrue1ProfessorProfessortrue1ProfessorProfessortrue1InstructorInstructortrue1Research Associate ProfessorResearch Associate Professortrue1ProfessorProfessortrue1Associate ProfessorAssociate Professortrue1ProfessorProfessortrue1Clinical AssociateClinical Associatetrue1ProfessorProfessortrue1ProfessorProfessortrue1Associate ProfessorAssociate Professortrue1PROFESSORPROFESSORtrue1ProfessorProfessorAuthorship 745124Authorship 7883615Authorship 79260525691772Romero IL, Mukherjee A, Kenny HA, Litchfield LM, Lengyel EClinical cancer research : an official journal of the American Association for Cancer ResearchMolecular pathways: trafficking of metabolic resources in the tumor microenvironment. Clin Cancer Res. 2015 Feb 15; 21(4):680-6.Clin Cancer Res2015-02-15T00:00:002015Molecular pathways: trafficking of metabolic resources in the tumor microenvironment.9555165Lengyel E, Somogyi A, Molnár T, Tóth E, Remenár E, Skriba Z, Esik OOrvosi hetilap[Juvenile aneuploid papillary cancer of the thyroid with pulmonary metastasis]. Orv Hetil. 1998 Mar 22; 139(12):687-90.Orv Hetil1998-03-22T00:00:001998[Juvenile aneuploid papillary cancer of the thyroid with pulmonary metastasis].25653139Kenny HA, Lal-Nag M, White EA, Shen M, Chiang CY, Mitra AK, Zhang Y, Curtis M, Schryver EM, Bettis S, Jadhav A, Boxer MB, Li Z, Ferrer M, Lengyel ENature communicationsQuantitative high throughput screening using a primary human three-dimensional organotypic culture predicts in vivo efficacy. Nat Commun. 2015 Feb 05; 6:6220.Nat Commun2015-02-05T00:00:002015Quantitative high throughput screening using a primary human three-dimensional organotypic culture predicts in vivo efficacy.Authorship 7960110Authorship 795597826017449Patch AM, Christie EL, Etemadmoghadam D, Garsed DW, George J, Fereday S, Nones K, Cowin P, Alsop K, Bailey PJ, Kassahn KS, Newell F, Quinn MC, Kazakoff S, Quek K, Wilhelm-Benartzi C, Curry E, Leong HS, Australian Ovarian Cancer Study Group, Hamilton A, Mileshkin L, Au-Yeung G, Kennedy C, Hung J, Chiew YE, Harnett P, Friedlander M, Quinn M, Pyman J, Cordner S, O'Brien P, Leditschke J, Young G, Strachan K, Waring P, Azar W, Mitchell C, Traficante N, Hendley J, Thorne H, Shackleton M, Miller DK, Arnau GM, Tothill RW, Holloway TP, Semple T, Harliwong I, Nourse C, Nourbakhsh E, Manning S, Idrisoglu S, Bruxner TJ, Christ AN, Poudel B, Holmes O, Anderson M, Leonard C, Lonie A, Hall N, Wood S, Taylor DF, Xu Q, Fink JL, Waddell N, Drapkin R, Stronach E, Gabra H, Brown R, Jewell A, Nagaraj SH, Markham E, Wilson PJ, Ellul J, McNally O, Doyle MA, Vedururu R, Stewart C, Lengyel E, Pearson JV, Waddell N, deFazio A, Grimmond SM, Bowtell DDNatureWhole-genome characterization of chemoresistant ovarian cancer. Nature. 2015 May 28; 521(7553):489-94.Nature2015-05-28T00:00:002015Whole-genome characterization of chemoresistant ovarian cancer.25838164Hunn J, Tenney ME, Tergas AI, Bishop EA, Moore K, Watkin W, Kirschner C, Hurteau J, Rodriguez GC, Lengyel E, Lee NK, Yamada SDGynecologic oncologyPatterns and utility of routine surveillance in high grade endometrial cancer. Gynecol Oncol. 2015 Jun; 137(3):485-9.Gynecol Oncol2015-03-30T00:00:002015Patterns and utility of routine surveillance in high grade endometrial cancer.1010Authorship 796561125839163Kinose Y, Sawada K, Nakamura K, Sawada I, Toda A, Nakatsuka E, Hashimoto K, Mabuchi S, Takahashi K, Kurachi H, Lengyel E, Kimura TOncotargetThe hypoxia-related microRNA miR-199a-3p displays tumor suppressor functions in ovarian carcinoma. Oncotarget. 2015 May 10; 6(13):11342-56.Oncotarget2015-05-10T00:00:002015The hypoxia-related microRNA miR-199a-3p displays tumor suppressor functions in ovarian carcinoma.Authorship 81721526115975Stringer-Reasor EM, Baker GM, Skor MN, Kocherginsky M, Lengyel E, Fleming GF, Conzen SDGynecologic oncologyGlucocorticoid receptor activation inhibits chemotherapy-induced cell death in high-grade serous ovarian carcinoma. Gynecol Oncol. 2015 Sep; 138(3):656-62.Gynecol Oncol2015-06-24T00:00:002015Glucocorticoid receptor activation inhibits chemotherapy-induced cell death in high-grade serous ovarian carcinoma.RicardoLastraRicardo Lastra0.000000000000000.000000000000003226Lastra, RicardoAssociate ProfessorAuthorship 82969826172303Litchfield LM, Mukherjee A, Eckert MA, Johnson A, Mills KA, Pan S, Shridhar V, Lengyel E, Romero ILOncotargetHyperglycemia-induced metabolic compensation inhibits metformin sensitivity in ovarian cancer. Oncotarget. 2015 Sep 15; 6(27):23548-60.Oncotarget2015-09-15T00:00:002015Hyperglycemia-induced metabolic compensation inhibits metformin sensitivity in ovarian cancer.Chicago60637ILAuthorship 840922426493647Bowtell DD, Böhm S, Ahmed AA, Aspuria PJ, Bast RC, Beral V, Berek JS, Birrer MJ, Blagden S, Bookman MA, Brenton JD, Chiappinelli KB, Martins FC, Coukos G, Drapkin R, Edmondson R, Fotopoulou C, Gabra H, Galon J, Gourley C, Heong V, Huntsman DG, Iwanicki M, Karlan BY, Kaye A, Lengyel E, Levine DA, Lu KH, McNeish IA, Menon U, Narod SA, Nelson BH, Nephew KP, Pharoah P, Powell DJ, Ramos P, Romero IL, Scott CL, Sood AK, Stronach EA, Balkwill FRNature reviews. CancerRethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer. Nat Rev Cancer. 2015 Nov; 15(11):668-79.Nat Rev Cancer2015-11-01T00:00:002015Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer.Authorship 845343Authorship 846827Authorship 847217825867073Kohlhapp FJ, Mitra AK, Lengyel E, Peter MEOncogeneMicroRNAs as mediators and communicators between cancer cells and the tumor microenvironment. Oncogene. 2015 Nov 26; 34(48):5857-68.Oncogene2015-04-13T00:00:002015MicroRNAs as mediators and communicators between cancer cells and the tumor microenvironment.25798837Mitra AK, Chiang CY, Tiwari P, Tomar S, Watters KM, Peter ME, Lengyel EOncogeneMicroenvironment-induced downregulation of miR-193b drives ovarian cancer metastasis. Oncogene. 2015 Nov 26; 34(48):5923-32.Oncogene2015-03-23T00:00:002015Microenvironment-induced downregulation of miR-193b drives ovarian cancer metastasis.26503049Patch AM, Christie EL, Etemadmoghadam D, Garsed DW, George J, Fereday S, Nones K, Cowin P, Alsop K, Bailey PJ, Kassahn KS, Newell F, Quinn MC, Kazakoff S, Quek K, Wilhelm-Benartzi C, Curry E, Leong HS, Australian Ovarian Cancer Study Group, Hamilton A, Mileshkin L, Au-Yeung G, Kennedy C, Hung J, Chiew YE, Harnett P, Friedlander M, Quinn M, Pyman J, Cordner S, O'Brien P, Leditschke J, Young G, Strachan K, Waring P, Azar W, Mitchell C, Traficante N, Hendley J, Thorne H, Shackleton M, Miller DK, Arnau GM, Tothill RW, Holloway TP, Semple T, Harliwong I, Nourse C, Nourbakhsh E, Manning S, Idrisoglu S, Bruxner TJ, Christ AN, Poudel B, Holmes O, Anderson M, Leonard C, Lonie A, Hall N, Wood S, Taylor DF, Xu Q, Fink JL, Waddell N, Drapkin R, Stronach E, Gabra H, Brown R, Jewell A, Nagaraj SH, Markham E, Wilson PJ, Ellul J, McNally O, Doyle MA, Vedururu R, Stewart C, Lengyel E, Pearson JV, Waddell N, deFazio A, Grimmond SM, Bowtell DDNatureCorrigendum: Whole-genome characterization of chemoresistant ovarian cancer. Nature. 2015 Nov 19; 527(7578):398.Nature2015-10-21T00:00:002015Corrigendum: Whole-genome characterization of chemoresistant ovarian cancer.Authorship 85757326780294Peters PN, Schryver EM, Lengyel E, Kenny HJournal of visualized experiments : JoVEModeling the Early Steps of Ovarian Cancer Dissemination in an Organotypic Culture of the Human Peritoneal Cavity. J Vis Exp. 2015 12 31; (106):e53541.J Vis Exp2015-12-31T00:00:002015Modeling the Early Steps of Ovarian Cancer Dissemination in an Organotypic Culture of the Human Peritoneal Cavity.Authorship 864491526838815Kenny HA, Lal-Nag M, White EA, Shen M, Chiang CY, Mitra AK, Zhang Y, Curtis M, Schryver EM, Bettis S, Jadhav A, Boxer MB, Li Z, Ferrer M, Lengyel ENature communicationsErratum: Quantitative high throughput screening using a primary human three-dimensional organotypic culture predicts in vivo efficacy. Nat Commun. 2016 Feb 03; 7:10649.Nat Commun2016-02-03T00:00:002016Erratum: Quantitative high throughput screening using a primary human three-dimensional organotypic culture predicts in vivo efficacy.Authorship 91097327103176Fehniger J, Thomas S, Lengyel E, Liao C, Tenney M, Oto A, Yamada SDGynecologic oncologyA prospective study evaluating diffusion weighted magnetic resonance imaging (DW-MRI) in the detection of peritoneal carcinomatosis in suspected gynecologic malignancies. Gynecol Oncol. 2016 07; 142(1):169-175.Gynecol Oncol2016-04-28T00:00:002016A prospective study evaluating diffusion weighted magnetic resonance imaging (DW-MRI) in the detection of peritoneal carcinomatosis in suspected gynecologic malignancies.Authorship 93272927561551Coscia F, Watters KM, Curtis M, Eckert MA, Chiang CY, Tyanova S, Montag A, Lastra RR, Lengyel E, Mann MNature communicationsIntegrative proteomic profiling of ovarian cancer cell lines reveals precursor cell associated proteins and functional status. Nat Commun. 2016 08 26; 7:12645.Nat Commun2016-08-26T00:00:002016Integrative proteomic profiling of ovarian cancer cell lines reveals precursor cell associated proteins and functional status.AbirMukherjeeAbir Mukherjee0.000000000000000.000000000000002809Mukherjee, AbirInstructorAuthorship 556913Authorship 606467Authorship 6186614Authorship 60872115698736Szavcsur P, Godény M, Bajzik G, Lengyel E, Repa I, Trón L, Boér A, Vincze B, Póti Z, Szabolcs I, Esik OEuropean journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical OncologyAngiography-proven liver metastases explain low efficacy of lymph node dissections in medullary thyroid cancer patients. Eur J Surg Oncol. 2005 Mar; 31(2):183-90.Eur J Surg Oncol2005-03-01T00:00:002005Angiography-proven liver metastases explain low efficacy of lymph node dissections in medullary thyroid cancer patients.23499550Ohyagi-Hara C, Sawada K, Kamiura S, Tomita Y, Isobe A, Hashimoto K, Kinose Y, Mabuchi S, Hisamatsu T, Takahashi T, Kumasawa K, Nagata S, Morishige K, Lengyel E, Kurachi H, Kimura TThe American journal of pathologymiR-92a inhibits peritoneal dissemination of ovarian cancer cells by inhibiting integrin a5 expression. Am J Pathol. 2013 May; 182(5):1876-89.Am J Pathol2013-03-15T00:00:002013miR-92a inhibits peritoneal dissemination of ovarian cancer cells by inhibiting integrin a5 expression.23237768Lengyel E, Fleming S, McEwen KA, Montag A, Temkin SMGynecologic oncologySerial sectioning of the fallopian tube allows for improved identification of primary fallopian tube carcinoma. Gynecol Oncol. 2013 Apr; 129(1):120-3.Gynecol Oncol2012-12-10T00:00:002012Serial sectioning of the fallopian tube allows for improved identification of primary fallopian tube carcinoma.23171795Mitra AK, Zillhardt M, Hua Y, Tiwari P, Murmann AE, Peter ME, Lengyel ECancer discoveryMicroRNAs reprogram normal fibroblasts into cancer-associated fibroblasts in ovarian cancer. Cancer Discov. 2012 Dec; 2(12):1100-8.Cancer Discov2012-11-21T00:00:002012MicroRNAs reprogram normal fibroblasts into cancer-associated fibroblasts in ovarian cancer.Authorship 956386Authorship 9572811Authorship 96024427746051Liu X, Romero IL, Litchfield LM, Lengyel E, Locasale JWCell metabolismMetformin Targets Central Carbon Metabolism and Reveals Mitochondrial Requirements in Human Cancers. Cell Metab. 2016 11 08; 24(5):728-739.Cell Metab2016-10-13T00:00:002016Metformin Targets Central Carbon Metabolism and Reveals Mitochondrial Requirements in Human Cancers.27758876Nakamura K, Sawada K, Kinose Y, Yoshimura A, Toda A, Nakatsuka E, Hashimoto K, Mabuchi S, Morishige KI, Kurachi H, Lengyel E, Kimura TMolecular cancer research : MCRExosomes Promote Ovarian Cancer Cell Invasion through Transfer of CD44 to Peritoneal Mesothelial Cells. Mol Cancer Res. 2017 01; 15(1):78-92.Mol Cancer Res2016-10-06T00:00:002016Exosomes Promote Ovarian Cancer Cell Invasion through Transfer of CD44 to Peritoneal Mesothelial Cells.27466355Zhang Y, Sriraman SK, Kenny HA, Luther E, Torchilin V, Lengyel EMolecular cancer therapeuticsReversal of Chemoresistance in Ovarian Cancer by Co-Delivery of a P-Glycoprotein Inhibitor and Paclitaxel in a Liposomal Platform. Mol Cancer Ther. 2016 10; 15(10):2282-2293.Mol Cancer Ther2016-07-27T00:00:002016Reversal of Chemoresistance in Ovarian Cancer by Co-Delivery of a P-Glycoprotein Inhibitor and Paclitaxel in a Liposomal Platform.Authorship 970161227856443Eckert MA, Pan S, Hernandez KM, Loth RM, Andrade J, Volchenboum SL, Faber P, Montag A, Lastra R, Peter ME, Yamada SD, Lengyel ECancer discoveryGenomics of Ovarian Cancer Progression Reveals Diverse Metastatic Trajectories Including Intraepithelial Metastasis to the Fallopian Tube. Cancer Discov. 2016 12; 6(12):1342-1351.Cancer Discov2016-10-07T00:00:002016Genomics of Ovarian Cancer Progression Reveals Diverse Metastatic Trajectories Including Intraepithelial Metastasis to the Fallopian Tube.